Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:9119
Name acute myeloid leukemia
Definition A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.
Source DiseaseOntology.org
Alt Ids DOID:9118 DOID:9171
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia myeloid leukemia acute myeloid leukemia

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE Tandutinib acute myeloid leukemia sensitive detail...
FLT3 G613_K614insYVDFREYEYDLKWEFRPRENLEFG Tandutinib acute myeloid leukemia sensitive detail...
FLT3 R595_L601dup Tandutinib acute myeloid leukemia sensitive detail...
FLT3 L610_E611insCSSDNEYFYVDFREYEYDLKWEFPRENL Tandutinib acute myeloid leukemia sensitive detail...
FLT3 Y599_D600insGLYVDFREYEY Tandutinib acute myeloid leukemia sensitive detail...
IDH2 R140Q AGI-6780 acute myeloid leukemia sensitive detail...
JAK2 V617F Go6976 acute myeloid leukemia sensitive detail...
JAK2 V617F A-1155463 acute myeloid leukemia sensitive detail...
IDH1 R132C Ivosidenib acute myeloid leukemia sensitive detail...
FLT3 D835H Crenolanib acute myeloid leukemia sensitive detail...
FLT3 Y842C Midostaurin acute myeloid leukemia sensitive detail...
FLT3 Y842C Imatinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins Ponatinib acute myeloid leukemia sensitive detail...
FLT3 act mut Cytarabine + Daunorubicin + Sunitinib acute myeloid leukemia sensitive detail...
CTNNB1 amp CWP232291 acute myeloid leukemia predicted - sensitive detail...
TET2 mutant Azacitidine acute myeloid leukemia predicted - sensitive detail...
FLT3 mutant Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 wild-type Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
DNMT3A mutant N/A acute myeloid leukemia not applicable detail...
FLT3 Y599_D600insSTDNEYFYVDFREYEY Azacitidine + Sorafenib acute myeloid leukemia predicted - sensitive detail...
FLT3 mutant Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 act mut Crenolanib acute myeloid leukemia sensitive detail...
FLT3 Y599_D600insSTDNEYFYVDFREYEY E6201 acute myeloid leukemia predicted - sensitive detail...
FLT3 Y599_D600insSTDNEYFYVDFREYEY FLX925 acute myeloid leukemia predicted - sensitive detail...
FLT3 mutant Azacitidine + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins IDH2 R140Q Enasidenib + Quizartinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Pacritinib acute myeloid leukemia predicted - sensitive detail...
NRAS G12D Binimetinib acute myeloid leukemia sensitive detail...
FLT3 Y599_D600insSTDNEYFYVDFREYEY Quizartinib acute myeloid leukemia predicted - sensitive detail...
NRAS G12D Alpelisib + Binimetinib acute myeloid leukemia sensitive detail...
KIT D816V Cytarabine + Dasatinib acute myeloid leukemia sensitive detail...
FLT3 mutant UNC2025 acute myeloid leukemia sensitive detail...
FGFR1 fusion Dovitinib acute myeloid leukemia sensitive detail...
JAK2 V617F Ruxolitinib + Tenalisib acute myeloid leukemia sensitive detail...
TP53 wild-type CTX-1 acute myeloid leukemia sensitive detail...
TP53 wild-type CTX-1 + Nutlin-3a acute myeloid leukemia sensitive detail...
IDH1 mutant N/A acute myeloid leukemia not applicable detail...
KMT2A rearrange N/A acute myeloid leukemia not applicable detail...
TET2 mutant N/A acute myeloid leukemia not applicable detail...
FLT3 mutant E6201 acute myeloid leukemia sensitive detail...
FLT3 act mut Palbociclib acute myeloid leukemia sensitive detail...
FLT3 wild-type Palbociclib acute myeloid leukemia sensitive detail...
FLT3 act mut Palbociclib + TCS 359 acute myeloid leukemia sensitive detail...
FLT3 wild-type Palbociclib + TCS 359 acute myeloid leukemia sensitive detail...
FLT3 act mut TCS 359 acute myeloid leukemia sensitive detail...
FLT3 wild-type TCS 359 acute myeloid leukemia sensitive detail...
FLT3 act mut Palbociclib + Quizartinib acute myeloid leukemia sensitive detail...
FLT3 act mut Palbociclib + Tandutinib acute myeloid leukemia sensitive detail...
FLT3 act mut Palbociclib + SGI-1776 acute myeloid leukemia sensitive detail...
NRAS mutant LY3009120 acute myeloid leukemia sensitive detail...
NRAS mutant Trametinib acute myeloid leukemia sensitive detail...
FLT3 mutant Crenolanib acute myeloid leukemia sensitive detail...
FLT3 D835X Crenolanib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Crenolanib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835X Crenolanib acute myeloid leukemia sensitive detail...
FLT3 D835Y E6201 acute myeloid leukemia sensitive detail...
FLT3 D835G E6201 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins E6201 acute myeloid leukemia sensitive detail...
DNMT3A mutant Decitabine acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins SHP099 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Quizartinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins ENMD-2076 acute myeloid leukemia sensitive detail...
IDH1 mutant Venetoclax acute myeloid leukemia predicted - sensitive detail...
IDH2 mutant Venetoclax acute myeloid leukemia predicted - sensitive detail...
IDH2 D76fs Venetoclax acute myeloid leukemia sensitive detail...
TP53 V173M APR-246 acute myeloid leukemia predicted - sensitive detail...
KIT N822K Ripretinib acute myeloid leukemia sensitive detail...
KIT N822K BPR1J373 acute myeloid leukemia sensitive detail...
KIT wild-type BPR1J373 acute myeloid leukemia sensitive detail...
FLT3 act mut VS-5584 acute myeloid leukemia sensitive detail...
NRAS mutant AZD5153 acute myeloid leukemia predicted - sensitive detail...
TP53 wild-type RO6839921 acute myeloid leukemia sensitive detail...
TP53 wild-type Cytarabine + RO6839921 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins MRX-2843 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y MRX-2843 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F691L MRX-2843 acute myeloid leukemia sensitive detail...
IDH1 R132X IDH305 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Altiratinib acute myeloid leukemia sensitive detail...
IDH2 R140Q Enasidenib acute myeloid leukemia sensitive detail...
IDH2 R172K Enasidenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Rebastinib acute myeloid leukemia no benefit detail...
IDH1 R132H BAY1436032 acute myeloid leukemia sensitive detail...
IDH1 R132L BAY1436032 acute myeloid leukemia sensitive detail...
IDH1 R132C BAY1436032 acute myeloid leukemia sensitive detail...
IDH1 R132S BAY1436032 acute myeloid leukemia sensitive detail...
IDH1 R132G BAY1436032 acute myeloid leukemia sensitive detail...
FLT3 mutant Zotiraciclib acute myeloid leukemia sensitive detail...
IDH2 mutant Enasidenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
KMT2A fusion I-BET151 + SGC0946 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Gilteritinib acute myeloid leukemia sensitive detail...
KMT2A fusion MI-503 acute myeloid leukemia predicted - sensitive detail...
KIT N822K Avapritinib acute myeloid leukemia sensitive detail...
FLT3 mutant Selinexor + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Selinexor + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 D835X Selinexor + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835X Selinexor + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Azacitidine + Quizartinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Cytarabine + Quizartinib acute myeloid leukemia sensitive detail...
JAK3 A572V Ilginatinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 Y842C Sunitinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 Y842C Sorafenib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 Y842C AGL2043 acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 Y842C Lestaurtinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 Y842C Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F691L Lestaurtinib acute myeloid leukemia decreased response detail...
FLT3 exon 14 ins FLT3 F691L Midostaurin acute myeloid leukemia decreased response detail...
FLT3 exon 14 ins FLT3 F621L Sunitinib acute myeloid leukemia decreased response detail...
FLT3 exon 14 ins FLT3 F621L AGL2043 acute myeloid leukemia decreased response detail...
FLT3 exon 14 ins FLT3 F621L Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F621L Lestaurtinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F621L Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins SKI-G-801 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Cytarabine + SKI-G-801 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins GTP-14564 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Ki23819 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Semaxanib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins N/A acute myeloid leukemia not applicable detail...
FLT3 exon 14 ins Decitabine + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Azacitidine + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Cytarabine + Daunorubicin + Quizartinib acute myeloid leukemia sensitive detail...
TP53 loss ALRN-6924 acute myeloid leukemia resistant detail...
TP53 R248Q ALRN-6924 acute myeloid leukemia resistant detail...
TP53 wild-type ALRN-6924 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins CG-806 acute myeloid leukemia sensitive detail...
FLT3 wild-type CG-806 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins FF-10101 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y FF-10101 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F691L FF-10101 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835H FF-10101 acute myeloid leukemia sensitive detail...
IDH2 R140Q IDH2 Q316E Enasidenib acute myeloid leukemia resistant detail...
IDH2 R140Q IDH2 I319M Enasidenib acute myeloid leukemia resistant detail...
IDH1 R132C IDH1 S280F Ivosidenib acute myeloid leukemia predicted - resistant detail...
FLT3 positive AGS62P1 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins FLT3 D835F Sorafenib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 D835F Crenolanib acute myeloid leukemia predicted - sensitive detail...
TP53 mutant Cytarabine + Venetoclax acute myeloid leukemia predicted - sensitive detail...
FLT3 mutant Cytarabine + Venetoclax acute myeloid leukemia sensitive detail...
IDH1 mutant Cytarabine + Venetoclax acute myeloid leukemia sensitive detail...
IDH2 mutant Cytarabine + Venetoclax acute myeloid leukemia sensitive detail...
DNMT3A mutant Pinometostat acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins KW-2449 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Sorafenib acute myeloid leukemia sensitive detail...
NRAS mutant Pazopanib acute myeloid leukemia predicted - resistant detail...
NRAS mutant Tivozanib acute myeloid leukemia predicted - resistant detail...
NRAS mutant Vemurafenib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins Entospletinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Ibrutinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins UNC1666 acute myeloid leukemia sensitive detail...
TP53 mutant CG-806 acute myeloid leukemia predicted - sensitive detail...
IDH1 R132X CG-806 acute myeloid leukemia predicted - sensitive detail...
IDH1 R132G Ivosidenib acute myeloid leukemia sensitive detail...
IDH1 R132H Ivosidenib acute myeloid leukemia sensitive detail...
IDH1 R132L Ivosidenib acute myeloid leukemia sensitive detail...
IDH1 R132S Ivosidenib acute myeloid leukemia sensitive detail...
IDH1 mutant LY3410738 acute myeloid leukemia predicted - sensitive detail...
IDH1 mutant Ivosidenib acute myeloid leukemia sensitive detail...
IDH2 R140L Enasidenib acute myeloid leukemia sensitive detail...
IDH2 R140G Enasidenib acute myeloid leukemia sensitive detail...
IDH2 R140W Enasidenib acute myeloid leukemia sensitive detail...
IDH2 R172M Enasidenib acute myeloid leukemia sensitive detail...
IDH2 R172G Enasidenib acute myeloid leukemia sensitive detail...
IDH2 R172S Enasidenib acute myeloid leukemia sensitive detail...
IDH2 R172W Enasidenib acute myeloid leukemia sensitive detail...
FLT3 D835X Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 I836X Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 D835X Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 I836X Gilteritinib acute myeloid leukemia sensitive detail...
KIT N822K Sunitinib acute myeloid leukemia predicted - sensitive detail...
KIT D816V Crenolanib acute myeloid leukemia sensitive detail...
KIT D816V Midostaurin acute myeloid leukemia sensitive detail...
KIT D816V Avapritinib acute myeloid leukemia sensitive detail...
KIT D816V Sorafenib acute myeloid leukemia resistant detail...
KIT D816V Quizartinib acute myeloid leukemia resistant detail...
KIT D816V Gilteritinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Avapritinib acute myeloid leukemia resistant detail...
IDH1 mutant Azacitidine acute myeloid leukemia sensitive detail...
IDH2 mutant Azacitidine acute myeloid leukemia sensitive detail...
IDH1 mutant Decitabine acute myeloid leukemia sensitive detail...
IDH2 mutant Decitabine acute myeloid leukemia sensitive detail...
TP53 mutant Decitabine acute myeloid leukemia sensitive detail...
TP53 mutant N/A acute myeloid leukemia not applicable detail...
DNMT3A R882H NRAS G12D I-BET151 acute myeloid leukemia sensitive detail...
DNMT3A R882H NRAS G12D Trametinib acute myeloid leukemia sensitive detail...
DNMT3A R882H NRAS G12D I-BET151 + Trametinib acute myeloid leukemia sensitive detail...
KIT N822K Imatinib acute myeloid leukemia decreased response detail...
KIT N822K Regorafenib acute myeloid leukemia sensitive detail...
KIT N822K Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon14 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon15 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon16 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon17 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon18 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon19 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon20 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon21 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon22 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon23 Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon14 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon15 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon16 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon17 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon18 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon19 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon20 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon21 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon22 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon23 Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 LOH Quizartinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3/CD3 Fabsc antibody acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 LOH FLT3/CD3 Fabsc antibody + Quizartinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins LAM-003 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y LAM-003 acute myeloid leukemia sensitive detail...
FLT3 D835Y LAM-003 acute myeloid leukemia predicted - sensitive detail...
FLT3 D835X LAM-003 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins LAM-003 + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Daunorubicin + LAM-003 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Cytarabine + LAM-003 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Gilteritinib + LAM-003 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins MK2206 + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins GSK690693 + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins A-1210477 + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Tandutinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y Sorafenib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 D835Y Tandutinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins LAM-003 + Tazemetostat acute myeloid leukemia sensitive detail...
IDH1 mutant Azacitidine + Venetoclax acute myeloid leukemia sensitive detail...
IDH1 mutant Decitabine + Venetoclax acute myeloid leukemia sensitive detail...
IDH2 mutant Azacitidine + Venetoclax acute myeloid leukemia sensitive detail...
IDH2 mutant Decitabine + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 mutant Decitabine + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 mutant Azacitidine + Venetoclax acute myeloid leukemia sensitive detail...
KMT2A fusion CDKI-73 acute myeloid leukemia sensitive detail...
IDH1 mutant Olaparib acute myeloid leukemia predicted - sensitive detail...
IDH2 mutant Olaparib acute myeloid leukemia predicted - sensitive detail...
IDH1 mutant Talazoparib acute myeloid leukemia predicted - sensitive detail...
IDH2 mutant Talazoparib acute myeloid leukemia predicted - sensitive detail...
IDH1 mutant Daunorubicin + Olaparib acute myeloid leukemia predicted - sensitive detail...
IDH2 mutant Daunorubicin + Olaparib acute myeloid leukemia predicted - sensitive detail...
IDH1 mutant Daunorubicin + Talazoparib acute myeloid leukemia predicted - sensitive detail...
IDH2 mutant Daunorubicin + Talazoparib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Sorafenib + Trametinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins PD-0325901 + Sorafenib acute myeloid leukemia sensitive detail...
NRAS Q61L PD-0325901 acute myeloid leukemia predicted - sensitive detail...
NRAS Q61L PD-0325901 + Sorafenib acute myeloid leukemia no benefit detail...
FLT3 D835Y Palbociclib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins CCT137690 + Palbociclib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins MK2206 + Palbociclib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Alisertib + Palbociclib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Ipatasertib + Palbociclib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 E654D Olverembatinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Olverembatinib acute myeloid leukemia sensitive detail...
TP53 mutant Azacitidine + Hu5F9-G4 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins A-419259 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Pexidartinib acute myeloid leukemia predicted - sensitive detail...
IDH1 R132X BAY1436032 acute myeloid leukemia no benefit detail...
TP53 R248Q thioureidobutyronitrile acute myeloid leukemia predicted - sensitive detail...
TP53 C242fs thioureidobutyronitrile acute myeloid leukemia predicted - sensitive detail...
TP53 I255N thioureidobutyronitrile acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins FLT3 D835Y Quizartinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 D835Y Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y Crenolanib acute myeloid leukemia conflicting detail...
FLT3 exon 14 ins FLT3 D835Y Midostaurin acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 D835I Quizartinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 D835I Gilteritinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins FLT3 D835I Sorafenib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D835I Crenolanib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D835I Sorafenib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D835I Gilteritinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D835I Quizartinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D835I Midostaurin acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins IACS-13909 acute myeloid leukemia predicted - sensitive detail...
NRAS Q61K UCM-1336 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins ARQ 531 acute myeloid leukemia not predictive detail...
FLT3 exon 14 ins Dubermatinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y Dubermatinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins NRAS G12D Dubermatinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins NRAS G12D Gilteritinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins IDH2 R140Q Dubermatinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins IDH2 R140Q Quizartinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins IDH2 R140Q Sorafenib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins IDH2 R140Q Midostaurin acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins JAK3 R953* Quizartinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins JAK3 V722I Sorafenib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins IDH2 R140Q Gilteritinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins IDH2 R140Q Crenolanib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins LT-171-861 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Cytarabine + LT-171-861 acute myeloid leukemia sensitive detail...
IDH1 R132C Azacitidine + Ivosidenib acute myeloid leukemia sensitive detail...
IDH1 R132H Azacitidine + Ivosidenib acute myeloid leukemia sensitive detail...
IDH1 R132L Azacitidine + Ivosidenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Abivertinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Abivertinib + Omacetaxine mepesuccinate acute myeloid leukemia sensitive detail...
KMT2A rearrange CYC065 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins OTS167 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Gilteritinib + OTS167 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins KX2-391 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y KX2-391 acute myeloid leukemia predicted - sensitive detail...
FLT3 I836del Cytarabine + Mitoxantrone + Sorafenib acute myeloid leukemia predicted - sensitive detail...
FLT3 I836del Azacitidine + Sorafenib + Venetoclax acute myeloid leukemia predicted - sensitive detail...
FLT3 F594_W603dup Gilteritinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins CUDC-907 + Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins AZD1480 + CUDC-907 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins APG-2575 + Olverembatinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins FLT3 N676K Midostaurin acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 D835Y Pexidartinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 N676K Pexidartinib acute myeloid leukemia predicted - resistant detail...
NRAS Q61L ASTX029 acute myeloid leukemia sensitive detail...
NRAS G12D ASTX029 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins ASTX029 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins ONO-7475 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins ONO-7475 + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins PF-04691502 + Quizartinib acute myeloid leukemia sensitive detail...
JAK2 V617F TP53 R248W IMG-7289 acute myeloid leukemia predicted - sensitive detail...
JAK2 V617F TP53 R248W IMG-7289 + Ruxolitinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Momelotinib acute myeloid leukemia sensitive detail...
IDH2 R140Q TQ05310 acute myeloid leukemia sensitive detail...
IDH2 R172K TQ05310 acute myeloid leukemia sensitive detail...
IDH1 mutant Azacitidine + Ivosidenib acute myeloid leukemia sensitive detail...
IDH1 R132G Azacitidine + Ivosidenib acute myeloid leukemia sensitive detail...
IDH1 R132S Azacitidine + Ivosidenib acute myeloid leukemia sensitive detail...
FLT3 act mut Azacitidine + Glasdegib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins NRAS G12C FF-10101 acute myeloid leukemia resistant detail...
FLT3 exon 14 ins NRAS Q61K FF-10101 acute myeloid leukemia resistant detail...
FLT3 exon 14 ins NRAS Q61K Quizartinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins NRAS G12C Quizartinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins NRAS G12C Gilteritinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins NRAS Q61K Gilteritinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 D835V FF-10101 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835N FF-10101 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 N841K FF-10101 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 N841Y FF-10101 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 Y842C FF-10101 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 A848P FF-10101 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins NRAS G12C FF-10101 + Trametinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins NRAS Q61K FF-10101 + Trametinib acute myeloid leukemia predicted - sensitive detail...
FLT3 mutant ERAS-601 + Gilteritinib acute myeloid leukemia predicted - sensitive detail...
FLT3 act mut Gilteritinib + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Gilteritinib + Venetoclax acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins FLT3 F691L Gilteritinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 D835H Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835V Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 N841K Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 Y842C Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 Y842C Quizartinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 F691L Quizartinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 D835H Quizartinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 D835V Quizartinib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 N841K Quizartinib acute myeloid leukemia resistant detail...
FLT3 N841Y Gilteritinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Saridegib + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Sonidegib + Sorafenib acute myeloid leukemia sensitive detail...
TP53 wild-type Siremadlin acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 15 ins Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon 15 ins Cytarabine + Daunorubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon 15 ins Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 15 ins Decitabine + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 15 ins Azacitidine + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 15 ins N/A acute myeloid leukemia not applicable detail...
FLT3 positive CLN-049 acute myeloid leukemia predicted - sensitive detail...
IDH1 mutant Olutasidenib acute myeloid leukemia sensitive detail...
IDH1 R132C Olutasidenib acute myeloid leukemia sensitive detail...
IDH1 R132G Olutasidenib acute myeloid leukemia sensitive detail...
IDH1 R132H Olutasidenib acute myeloid leukemia sensitive detail...
IDH1 R132L Olutasidenib acute myeloid leukemia sensitive detail...
IDH1 R132S Olutasidenib acute myeloid leukemia sensitive detail...
KMT2A rearrange FLT3 exon 14 ins Revumenib acute myeloid leukemia sensitive detail...
KMT2A rearrange FLT3 exon 14 ins Revumenib + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Crenolanib + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835H Sorafenib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 N841K Sorafenib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 V843A Sorafenib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 D835Y Crenolanib + Sorafenib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 D835N Crenolanib + Sorafenib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 D835A Crenolanib + Sorafenib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 N841Y Crenolanib + Sorafenib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 N841K Crenolanib + Sorafenib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 D835X NRAS G13D Gilteritinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 D835X NRAS G12D NRAS G12S Gilteritinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D835X Gilteritinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 D835X NRAS G13R Gilteritinib acute myeloid leukemia predicted - resistant detail...
CBL Q367_E373delinsRLK FLT3 exon 14 ins FLT3 D835X NRAS G12D Gilteritinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 D835X NRAS Q61K Gilteritinib acute myeloid leukemia predicted - resistant detail...
BRAF G469A CBL C404Y FLT3 exon 14 ins FLT3 D835X Gilteritinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 D835X NRAS Q61R Gilteritinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 D835X NRAS G13C NRAS G13R Gilteritinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 D835X NRAS Q61H Gilteritinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins NRAS G12C Gilteritinib + Trametinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins NRAS Q61K Gilteritinib + Trametinib acute myeloid leukemia sensitive detail...
IDH1 R132H IDH1 D279N Ivosidenib acute myeloid leukemia predicted - resistant detail...
IDH1 R132H IDH1 D279N LY3410738 acute myeloid leukemia sensitive detail...
IDH1 R132C IDH1 D279N IDH2 R140Q Ivosidenib acute myeloid leukemia predicted - resistant detail...
IDH1 R119P IDH1 R132S Ivosidenib acute myeloid leukemia predicted - resistant detail...
IDH1 G131A IDH1 R132C Ivosidenib acute myeloid leukemia predicted - resistant detail...
IDH1 R132C IDH1 D279N IDH1 H315D Ivosidenib acute myeloid leukemia predicted - resistant detail...
IDH1 R119P IDH1 R132L IDH2 R140Q Ivosidenib acute myeloid leukemia predicted - resistant detail...
IDH1 R132G IDH1 D279N IDH1 G289D Ivosidenib acute myeloid leukemia predicted - resistant detail...
IDH1 R132L IDH2 R140Q Ivosidenib acute myeloid leukemia predicted - resistant detail...
IDH1 R132C IDH2 R140Q Ivosidenib acute myeloid leukemia predicted - resistant detail...
IDH1 R132H IDH2 R140Q Ivosidenib acute myeloid leukemia predicted - resistant detail...
IDH1 R119P IDH1 R132L Ivosidenib acute myeloid leukemia predicted - resistant detail...
IDH1 R132C IDH1 T313I Ivosidenib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 D835H Crenolanib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 V843I Crenolanib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 G846C Sorafenib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins FLT3 F691L Crenolanib + Sorafenib acute myeloid leukemia resistant detail...
IDH2 R140Q IDH2 E343V Enasidenib acute myeloid leukemia predicted - resistant detail...
IDH2 R140Q IDH2 A347T Enasidenib acute myeloid leukemia predicted - resistant detail...
IDH2 R140Q IDH2 V351I Enasidenib acute myeloid leukemia predicted - resistant detail...
TET2 del Selinexor acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F691L Tuspetinib acute myeloid leukemia predicted - sensitive detail...
TET2 del Eltanexor acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y Tuspetinib acute myeloid leukemia predicted - sensitive detail...
IDH2 act mut TQB3455 acute myeloid leukemia predicted - sensitive detail...
IDH2 R172K TQB3455 acute myeloid leukemia predicted - sensitive detail...
KMT2A rearrange Revumenib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Sitravatinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins PHI-101 acute myeloid leukemia predicted - sensitive detail...
FLT3 Y842D Cytarabine + Idarubicin + Midostaurin acute myeloid leukemia predicted - sensitive detail...
FLT3 V592G Sorafenib acute myeloid leukemia predicted - sensitive detail...
FLT3 N676K Sorafenib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins FLT3 D835Y Pacritinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Cytarabine + Daunorubicin + Pacritinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Decitabine + Pacritinib acute myeloid leukemia predicted - sensitive detail...
IDH1 R132X LY3410738 acute myeloid leukemia predicted - sensitive detail...
IDH2 R172X LY3410738 acute myeloid leukemia predicted - sensitive detail...
IDH2 R140X LY3410738 acute myeloid leukemia predicted - sensitive detail...
FLT3 act mut NMS-P088 acute myeloid leukemia predicted - sensitive detail...
FLT3 act mut BMF-500 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins BMF-500 acute myeloid leukemia predicted - sensitive detail...
TET2 mutant Olaparib acute myeloid leukemia sensitive detail...
DNMT3A mutant Olaparib acute myeloid leukemia resistant detail...
DNMT3A mut TET2 mut Olaparib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins TET2 mut Olaparib + Quizartinib acute myeloid leukemia sensitive detail...
DNMT3A mut FLT3 exon 14 ins TET2 mut Olaparib + Quizartinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins TET2 mut Doxorubicin + Olaparib + Quizartinib acute myeloid leukemia sensitive detail...
DNMT3A mut FLT3 exon 14 ins TET2 mut Doxorubicin + Olaparib + Quizartinib acute myeloid leukemia sensitive detail...
TET2 A1505T TET2 mut Olaparib acute myeloid leukemia sensitive detail...
TET2 loss Olaparib acute myeloid leukemia sensitive detail...
DNMT3A loss TET2 loss Olaparib acute myeloid leukemia sensitive detail...
DNMT3A loss Olaparib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins TET2 loss Olaparib + Quizartinib acute myeloid leukemia sensitive detail...
DNMT3A loss FLT3 exon 14 ins TET2 loss Olaparib + Quizartinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins TET2 loss Doxorubicin + Olaparib + Quizartinib acute myeloid leukemia sensitive detail...
DNMT3A loss FLT3 exon 14 ins TET2 loss Doxorubicin + Olaparib + Quizartinib acute myeloid leukemia sensitive detail...
TET2 loss Talazoparib acute myeloid leukemia sensitive detail...
DNMT3A loss TET2 loss Talazoparib acute myeloid leukemia sensitive detail...
DNMT3A loss Talazoparib acute myeloid leukemia resistant detail...
FLT3 exon 14 ins TET2 loss Quizartinib + Talazoparib acute myeloid leukemia sensitive detail...
DNMT3A loss FLT3 exon 14 ins TET2 loss Quizartinib + Talazoparib acute myeloid leukemia sensitive detail...
DNMT3A loss FLT3 exon 14 ins Quizartinib + Talazoparib acute myeloid leukemia no benefit detail...
JAK2 V617F TET2 loss Olaparib + Rituximab acute myeloid leukemia sensitive detail...
JAK2 V617F TET2 loss Hydroxyurea + Olaparib + Rituximab acute myeloid leukemia sensitive detail...
TET2 del Olaparib acute myeloid leukemia sensitive detail...
DNMT3A del TET2 del Olaparib acute myeloid leukemia sensitive detail...
DNMT3A del Olaparib acute myeloid leukemia resistant detail...
FLT3 exon 15 ins Quizartinib acute myeloid leukemia sensitive detail...
TP53 E180R Cytarabine + Doxorubicin acute myeloid leukemia sensitive detail...
FLT3 Q575del Cytarabine + Daunorubicin + Gilteritinib acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins PLM-101 acute myeloid leukemia sensitive detail...
FLT3 exon 15 ins Cytarabine + Daunorubicin + Quizartinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Cytarabine + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon 15 ins Cytarabine + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon 15 ins Cytarabine + Quizartinib acute myeloid leukemia sensitive detail...
FLT3 exon14 Cytarabine + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon15 Cytarabine + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon16 Cytarabine + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon17 Cytarabine + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon18 Cytarabine + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon19 Cytarabine + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon20 Cytarabine + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon21 Cytarabine + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon22 Cytarabine + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon23 Cytarabine + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon14 Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon15 Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon16 Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon17 Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon18 Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon19 Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon20 Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon21 Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon22 Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon23 Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon 15 ins Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D835Y Gilteritinib acute myeloid leukemia predicted - resistant detail...
FLT3 exon 14 ins RMC-4550 acute myeloid leukemia sensitive detail...
KIT N822K RMC-4550 acute myeloid leukemia decreased response detail...
FLT3 exon 14 ins FLT3 D835H RMC-4550 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835V RMC-4550 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y RMC-4550 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 N841K RMC-4550 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 Y842C RMC-4550 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F691L RMC-4550 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins TP-0184 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins TP-0184 + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins NRAS Q61K RMC-4550 acute myeloid leukemia resistant detail...
FLT3 exon 14 ins NRAS G12C RMC-4550 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins NRAS Q61K Gilteritinib + RMC-4550 acute myeloid leukemia resistant detail...
FLT3 exon 14 ins NRAS G12C Gilteritinib + RMC-4550 acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins RMC-4550 + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins NRAS G12C RMC-4550 + Venetoclax acute myeloid leukemia sensitive detail...
KIT N822K RMC-4550 + Venetoclax acute myeloid leukemia sensitive detail...
KIT N822K Trametinib + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Trametinib + Venetoclax acute myeloid leukemia sensitive detail...
NRAS Q61L RMC-4550 acute myeloid leukemia resistant detail...
NRAS G12D RMC-4550 acute myeloid leukemia resistant detail...
FLT3 exon 14 ins HC-7366 + Venetoclax acute myeloid leukemia predicted - sensitive detail...
KMT2A rearrange Fingolimod acute myeloid leukemia sensitive detail...
KMT2A rearrange Daunorubicin + Fingolimod acute myeloid leukemia sensitive detail...
FLT3 act mut Azacitidine + Gilteritinib + Venetoclax acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins NRAS G12C Foretinib acute myeloid leukemia decreased response detail...
FLT3 exon 14 ins Foretinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Azacitidine + Gilteritinib + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 D835X Azacitidine + Gilteritinib + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 D835V Foretinib acute myeloid leukemia sensitive detail...
FLT3 D835E Foretinib acute myeloid leukemia sensitive detail...
FLT3 D835V Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 D835E Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 D835V Quizartinib acute myeloid leukemia decreased response detail...
FLT3 D835E Quizartinib acute myeloid leukemia decreased response detail...
FLT3 exon 14 ins FLT3 D835V Foretinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y Foretinib acute myeloid leukemia sensitive detail...
NRAS Q61L AMG 176 + Trametinib acute myeloid leukemia sensitive detail...
NRAS Q61L AZD5991 + Trametinib acute myeloid leukemia sensitive detail...
NRAS Q61L AMG 176 + Selumetinib acute myeloid leukemia sensitive detail...
NRAS Q61L AZD5991 + Selumetinib acute myeloid leukemia sensitive detail...
NRAS Q61L BCL201 + Selumetinib acute myeloid leukemia sensitive detail...
NRAS Q61L Trametinib + Venetoclax acute myeloid leukemia sensitive detail...
NRAS Q61L Selumetinib + Venetoclax acute myeloid leukemia sensitive detail...
IDH2 R140Q Enasidenib + Venetoclax acute myeloid leukemia predicted - sensitive detail...
IDH2 R172K Enasidenib + Venetoclax acute myeloid leukemia predicted - sensitive detail...
IDH2 R172W Enasidenib + Venetoclax acute myeloid leukemia predicted - sensitive detail...
KMT2A rearrange JNJ-75276617 + Venetoclax acute myeloid leukemia predicted - sensitive detail...
KMT2A rearrange Azacitidine + JNJ-75276617 acute myeloid leukemia predicted - sensitive detail...
FLT3 exon 14 ins Decitabine + Quizartinib + Venetoclax acute myeloid leukemia predicted - sensitive detail...
JAK2 V617F Flonoltinib maleate acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Flonoltinib maleate acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Ningetinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F691L Ningetinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Gilteritinib + Metformin acute myeloid leukemia sensitive detail...
KMT2A rearrange FHD-286 acute myeloid leukemia sensitive detail...
KMT2A rearrange Decitabine + FHD-286 acute myeloid leukemia sensitive detail...
KMT2A rearrange Birabresib + FHD-286 acute myeloid leukemia sensitive detail...
KMT2A rearrange FHD-286 + Revumenib acute myeloid leukemia sensitive detail...
KMT2A rearrange FHD-286 + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins MRX-2843 + Venetoclax acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Cytarabine + Idarubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon 15 ins Cytarabine + Idarubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon14 Cytarabine + Idarubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon15 Cytarabine + Idarubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon16 Cytarabine + Idarubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon17 Cytarabine + Idarubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon18 Cytarabine + Idarubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon19 Cytarabine + Idarubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon20 Cytarabine + Idarubicin + Midostaurin acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Cytarabine + Idarubicin + Quizartinib acute myeloid leukemia sensitive detail...
FLT3 exon 15 ins Cytarabine + Idarubicin + Quizartinib acute myeloid leukemia sensitive detail...
IDH2 mutant Azacitidine + Enasidenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Bemcentinib + Sorafenib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Bemcentinib + Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Dubermatinib + Gilteritinib acute myeloid leukemia sensitive detail...
FLT3 exon 14 ins Dubermatinib + Sorafenib acute myeloid leukemia sensitive detail...
KMT2A rearrange Ziftomenib acute myeloid leukemia no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status USA 0
NCT00513474 Phase I Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant Completed USA 0
NCT00679536 Phase Ib/II anti-thymocyte globulin + Busulfan + Fludarabine Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Unknown status USA 0
NCT00801489 Phase II Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin + Idarubicin Fludarabine, Cytarabine, Filgrastim, Gemtuzumab Ozogamicin, and Idarubicin in Core Binding Factor (CBF) Leukemias Recruiting USA 0
NCT00857389 Phase II Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed USA 0
NCT00866281 Phase Ib/II Midostaurin A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia Terminated USA | SWE | NLD | ITA | FRA 0
NCT00887068 Phase III Azacitidine Randomized Allogeneic Azacitidine Study Completed USA 0
NCT00892190 Phase I Dasatinib Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome Completed USA 0
NCT00908167 Phase I Clofarabine + Cytarabine + Sorafenib Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies Completed USA 0
NCT00946647 Phase II Panobinostat Azacitidine A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). Completed USA | SWE | ITA | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT 2
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Terminated USA 0
NCT01084252 Phase Ib/II Isatuximab Dexamethasone + Isatuximab Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies Completed USA | TUR | ITA | ISR | GRC | GBR | FRA | FIN | ESP | BRA | BEL | ARG 5
NCT01093573 Phase Ib/II Azacitidine + Midostaurin Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia Completed USA 0
NCT01187810 Phase I Fenretinide Cytarabine Methotrexate Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL Terminated USA 0
NCT01211457 Phase Ib/II Sapacitabine + Venetoclax Decitabine + Sapacitabine Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes Unknown status USA 0
NCT01222143 Phase Ib/II Cytarabine + Etoposide + Mitoxantrone Nilotinib Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia Terminated CAN 0
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed USA | DNK 0
NCT01252667 Phase II Cyclosporine + Mycophenolate mofetil Clofarabine Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant Completed USA 0
NCT01266083 Phase II WT1 vaccine Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Completed USA 0
NCT01303796 Phase III Decitabine + Sapacitabine Decitabine A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS) Completed USA | SWE | POL | ITA | HUN | GBR | FRA | ESP | DEU | CHE | BEL | AUT 0
NCT01305499 Phase II Azacitidine + Entinostat A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) Active, not recruiting USA 0
NCT01321346 Phase I Cytarabine Panobinostat A Study Of Panobinostat In Children With Refractory Hematologic Malignancies Completed USA 0
NCT01338987 Phase II Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation Completed USA 0
NCT01352650 Phase I Decitabine + Plerixafor Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) Completed USA 0
NCT01371981 Phase III Cytarabine + Daunorubicin + Etoposide Sorafenib Cytarabine + Etoposide Cytarabine + Mitoxantrone Asparaginase + Cytarabine Bortezomib Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA | NZL | CAN | AUS 1
NCT01398462 Phase I CWP232291 Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients Completed USA 1
NCT01449058 Phase Ib/II Alpelisib + Binimetinib A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Completed USA | ITA | GBR | FRA | ESP | CHE | AUS 0
NCT01463046 Phase I Cytarabine + Daunorubicin + Panobinostat Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Completed USA 0
NCT01483274 Phase I Decitabine Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation Withdrawn USA 0
NCT01498445 Phase Ib/II Dasatinib + Decitabine An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) Terminated USA 0
NCT01515527 Phase II Cytarabine Cladribine Decitabine Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) Recruiting USA 0
NCT01534260 Phase Ib/II Bortezomib + Sorafenib + Vorinostat Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype Completed USA 0
NCT01546038 Phase Ib/II Glasdegib Cytarabine Decitabine Cytarabine + Daunorubicin A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA | POL | ITA | ESP | DEU | CAN 0
NCT01578109 Phase I Sorafenib Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia Completed USA 0
NCT01606579 Phase Ib/II Cytarabine + PRI-724 Dasatinib + PRI-724 PRI-724 Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies Completed USA 0
NCT01620216 Phase II Sunitinib Dasatinib Nilotinib Ponatinib Sorafenib Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients Terminated USA 0
NCT01621477 Phase II Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Terminated USA 0
NCT01621542 Phase I WT2725 Clinical Study of WT2725 in Patients With Advanced Malignancies Completed USA 0
NCT01627041 Phase II Cytarabine + Daunorubicin + Decitabine Cytarabine + Daunorubicin Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia Unknown status USA 0
NCT01634217 Phase I Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation Completed USA 0
NCT01640301 Phase Ib/II Aldesleukin WT1 sensitized T cells Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant Terminated USA 0
NCT01657682 Phase II Crenolanib A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations Completed USA 0
NCT01685411 Phase 0 Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam Busulfan and Cyclophosphamide Followed By ALLO BMT Terminated USA 0
NCT01687400 Phase II Decitabine Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed USA 0
NCT01690624 Phase I BI 836858 BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse Completed USA 0
NCT01707004 Phase I Cyclophosphamide Decitabine Filgrastim Fludarabine Busulfan Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed USA 0
NCT01729845 Phase Ib/II Cytarabine + Etoposide + Mitoxantrone Decitabine Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed USA 0
NCT01736943 Phase II Bortezomib + Pegylated liposomal doxorubicin Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia Completed USA 0
NCT01744223 Phase Ib/II Rimiducid Rivogenlecleucel Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Active, not recruiting USA 0
NCT01746849 Phase II Leuprolide Cyclophosphamide Thiotepa Palifermin Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting USA 0
NCT01773395 Phase II Busulfan + Fludarabine + Methotrexate + Tacrolimus Busulfan + Fludarabine + GVAX + Methotrexate + Tacrolimus GVAX vs. Placebo for MDS/AML After Allo HSCT Terminated USA 0
NCT01786343 Phase II Decitabine Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML) Completed USA 0
NCT01794702 Phase Ib/II Idarubicin Clofarabine Cytarabine Decitabine Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia Completed USA 0
NCT01798901 Phase I Decitabine + REC-2282 AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia Completed USA 0
NCT01804101 Phase I CPX-351 Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed USA 0
NCT01806571 Phase II Cytarabine + Daunorubicin Nilotinib Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed USA 0
NCT01814826 Phase I MLN4924 Azacitidine Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older Completed USA 0
NCT01822015 Phase I Cytarabine + Idarubicin + Sirolimus Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed USA 0
NCT01823198 Phase Ib/II Methotrexate anti-thymocyte globulin + Busulfan + Fludarabine Tacrolimus Filgrastim Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies Completed USA 0
NCT01829503 Phase II Cytarabine + Decitabine Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Completed USA 0
NCT01834248 Phase I Decitabine + Rasdegafusp alfa DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed USA 0
NCT01835288 Phase II Arsenic trioxide Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Withdrawn 0
NCT01838395 Phase II BKT140 + Cytarabine Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients Completed USA | ISR 0
NCT01841333 Phase II Glasdegib PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant Completed USA 0
NCT01842646 Phase II Glasdegib Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) Completed USA 0
NCT01846624 Phase II Decitabine + Midostaurin Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Terminated USA 0
NCT01849276 Phase I Cytarabine + Metformin Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Terminated USA 0
NCT01861314 Phase I Bortezomib + Decitabine + Sorafenib Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia Active, not recruiting USA 0
NCT01869114 Phase II Azacitidine + Sirolimus Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Active, not recruiting USA 0
NCT01869803 Phase I Gemtuzumab ozogamicin Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia Approved for marketing USA 0
NCT01870596 Phase II Cytarabine MK-8776 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed USA 0
NCT01876953 Phase Ib/II Cytarabine + Dasatinib + Idarubicin Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia Terminated USA 0
NCT01880437 Phase II Cytarabine + Vismodegib A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome Terminated USA | DEU | CAN 0
NCT01883362 Phase II Midostaurin Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Completed USA | CAN 0
NCT01885689 Phase II Clofarabine + Melphalan Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission Active, not recruiting USA 0
NCT01885897 Phase Ib/II Nogapendekin alfa inbakicept IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Completed USA 0
NCT01892371 Phase Ib/II Azacitidine + Quizartinib Cytarabine + Quizartinib Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT01893320 Phase Ib/II Decitabine + Vosaroxin Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Completed USA 0
NCT01898793 Phase Ib/II m-ceNK cells Aldesleukin + Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Nogapendekin alfa inbakicept Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Terminated USA 0
NCT01907815 Phase II Trametinib + Uprosertib Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia Terminated USA 0
NCT01915498 Phase Ib/II Enasidenib Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation Completed USA | FRA 0
NCT01926587 Phase Ib/II Azacitidine + Regorafenib Oral Rigosertib in Combination With Azacitidine Completed USA | FRA 0
NCT01943682 Phase I CPX-351 Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Completed USA 0
NCT01961765 Phase I Cabozantinib Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed USA 0
NCT02003573 Phase I Decitabine + Volasertib Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) Terminated USA 0
NCT02010645 Phase II Decitabine + Eltrombopag Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) Terminated USA 0
NCT02016729 Phase I Trametinib KRT-232 A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia Completed USA 0
NCT02019069 Phase II CPX-351 CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT02029417 Phase II Cytarabine + Decitabine + Omacetaxine mepesuccinate Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Terminated USA 0
NCT02039726 Phase III Cytarabine + Fludarabine Cytarabine + Etoposide + Mitoxantrone Quizartinib Filgrastim + Idarubicin (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive Completed USA | POL | NLD | ITA | HUN | HRV | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS 5
NCT02046122 Phase I Cytarabine + Idarubicin Adoptive Transfer of Haplo-identical DLI for AML and MDS Completed USA 0
NCT02049801 Phase I Binimetinib + Cytarabine + Idarubicin MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Terminated USA 0
NCT02057770 Phase I Busulfan + Cyclophosphamide + Fludarabine Tocilizumab Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Terminated USA 0
NCT02071927 Phase I Telaglenastat Study of the Glutaminase Inhibitor CB-839 in Leukemia Completed USA 0
NCT02073838 Phase II Decitabine Ribavirin + Vismodegib Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML Completed CAN 0
NCT02078609 Phase I LGH447 A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) Completed USA | NLD | ITA | FRA | DEU | AUS 1
NCT02083250 Phase I anti-thymocyte globulin Vorinostat Busulfan + Clofarabine + Fludarabine Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia Completed USA 0
NCT02085408 Phase III Clofarabine Cytarabine + Daunorubicin Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA | ISR 1
NCT02088541 Phase II Cytarabine Azacitidine Decitabine Selinexor Hydroxyurea Selinexor (KPT-330) in Older Patients With Relapsed AML Completed USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN 0
NCT02089230 Phase Ib/II Binimetinib MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy Terminated USA 0
NCT02091245 Phase I Selinexor Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML Active, not recruiting USA 0
NCT02093403 Phase I Decitabine + Selinexor Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed USA 0
NCT02096055 Phase II Cladribine Guadecitabine Idarubicin 4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML) Completed USA 0
NCT02098967 Phase I RO6839921 A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia. Completed USA | CAN 0
NCT02109627 Phase I Cytarabine + Ficlatuzumab Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML Terminated USA 0
NCT02109744 Phase Ib/II Decitabine + Sirolimus Decitabine + Ribavirin Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients Completed USA 0
NCT02115295 Phase II Cladribine + Cytarabine + Idarubicin Midostaurin Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) Recruiting USA 0
NCT02117297 Phase II Gemtuzumab ozogamicin SCT Plus Immune Therapy in Average Risk AML/MDS Completed USA 0
NCT02121418 Phase I Cytarabine + Decitabine Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm Completed USA 0
NCT02126553 Phase II Lenalidomide Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission Completed USA 0
NCT02141477 Phase II Decitabine + Omacetaxine mepesuccinate Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Terminated USA 0
NCT02141828 Phase I Pinometostat A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene Completed USA | CAN 0
NCT02143635 Phase I Siremadlin Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt Completed USA | NLD | FRA | ESP | DEU 3
NCT02152956 Phase Ib/II Flotetuzumab Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS Terminated USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU 0
NCT02159495 Phase I Cyclophosphamide Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting USA 0
NCT02177812 Phase I GSK2879552 A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) Terminated USA | CAN | AUS 0
NCT02181478 Phase I Fludarabine Cyclophosphamide Intra-Osseous Co-Transplant of UCB and hMSC Completed USA 0
NCT02190695 Phase II Carboplatin + Decitabine Arsenic trioxide + Decitabine A Safety and Efficacy Study Using Decitabine, Decitabine/Carboplatin, Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia , Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Completed USA 0
NCT02193958 Phase Ib/II FF-10501-01 Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies Completed USA 0
NCT02196857 Phase II Azacitidine + Sorafenib Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation Completed USA 0
NCT02200380 Phase II Plerixafor CDX-301 A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Terminated USA 0
NCT02203773 Phase I Decitabine + Venetoclax Azacitidine + Venetoclax Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo) Terminated USA | FRA | DEU | AUS 0
NCT02203903 Phase I MultiTAA-specific T cells Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) Recruiting USA 0
NCT02204020 Phase II Azacitidine Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS Withdrawn USA 0
NCT02204085 Phase Ib/II GO-203-2C A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting USA 0
NCT02212561 Phase Ib/II Selinexor Cytarabine Cytarabine + Dexamethasone + Methotrexate Fludarabine Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT02221310 Phase II Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS Completed USA 0
NCT02236013 Phase I Cytarabine + Idarubicin Gilteritinib A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Completed USA 0
NCT02238522 Phase I Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML Withdrawn USA 0
NCT02250937 Phase II Cladribine Busulfan Busulfan + Venetoclax Fludarabine Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Active, not recruiting USA 0
NCT02257138 Phase Ib/II Decitabine + Ruxolitinib Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML) Completed USA 0
NCT02267863 Phase I APTO-253 A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS Terminated USA 0
NCT02269579 Phase II CPX-351 Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment Withdrawn USA 0
NCT02270463 Phase Ib/II Tagraxofusp-erzs SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission Terminated USA 0
NCT02270788 Phase I Cytarabine + Leucovorin + Methotrexate Crenolanib + Sorafenib Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies Completed USA 0
NCT02273102 Phase I Tranylcypromine + Tretinoin Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA) Completed USA 0
NCT02275533 Phase II Nivolumab Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy Active, not recruiting USA | CAN 0
NCT02283177 Phase II Crenolanib + Cytarabine + Daunorubicin A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations Completed USA 0
NCT02286726 Phase II CPX-351 CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia Completed USA 0
NCT02287233 Phase I Cytarabine + Venetoclax A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML) Completed USA | ITA | DEU | AUS 0
NCT02296242 Phase Ib/II Ulixertinib Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes Completed USA 0
NCT02299518 Phase I Etoposide Selinexor Cytarabine + Etoposide + Mitoxantrone Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed USA 0
NCT02305563 Phase Ib/II Cytarabine + Ulocuplumab An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia Terminated USA | ROU | ITA | ISR | CAN | BRA 4
NCT02306291 Phase Ib/II Cytarabine + Idarubicin Cytarabine + Etoposide + Mitoxantrone Uproleselan Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML Completed USA | IRL | AUS 0
NCT02308761 Phase I TEN-010 A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Completed USA 0
NCT02312102 Phase I Bortezomib + Lenalidomide Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation Active, not recruiting USA 0
NCT02319369 Phase I Milademetan Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies Terminated USA 0
NCT02323113 Phase Ib/II Mivavotinib Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) Terminated USA | CAN 0
NCT02323607 Phase I Cytarabine + Daunorubicin + Pacritinib Decitabine + Pacritinib Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations Completed USA 0
NCT02333162 Phase I Mycophenolate mofetil Tacrolimus Fludarabine + Melphalan Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Recruiting USA 0
NCT02335814 Phase I FLX925 First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia Terminated USA 0
NCT02343939 Phase Ib/II Decitabine Cytarabine + Daunorubicin Entospletinib Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) Terminated USA | DEU | CAN 0
NCT02348489 Phase III Guadecitabine Cytarabine Azacitidine Decitabine SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction Completed USA | SWE | ROU | POL | NLD | ITA | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BGR | BEL | AUT | AUS 5
NCT02351037 Phase II Ibrutinib Cytarabine A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia Terminated USA 0
NCT02356159 Phase Ib/II Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Active, not recruiting USA 0
NCT02367456 Phase Ib/II Azacitidine + Glasdegib A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients Completed USA | GBR | FRA | DEU | CAN | BEL 0
NCT02381548 Phase I Adavosertib + Belinostat Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia Terminated USA 0
NCT02391480 Phase I Mivebresib A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Completed USA 0
NCT02397720 Phase II Azacitidine + Nivolumab A Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia Completed USA 0
NCT02400255 Phase II Crenolanib Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients Completed USA 0
NCT02400281 Phase Ib/II Azacitidine Crenolanib Cytarabine + Idarubicin Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients Completed USA 0
NCT02403310 Phase I Cytarabine + Daunorubicin Selinexor A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML Completed USA 0
NCT02412475 Phase I Cytarabine Sorafenib Vorinostat Filgrastim Daunorubicin Fludarabine Decitabine Epigenetic Reprogramming in Relapse AML Terminated USA 0
NCT02416388 Phase II Cytarabine + Daunorubicin Cytarabine + Vosaroxin Cytarabine Methotrexate + Mycophenolic Acid Cyclosporine + Mycophenolic Acid Cytarabine + Venetoclax Cytarabine + Dexamethasone Cyclosporine Cytarabine + Idarubicin Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR (BIG-1) Recruiting FRA 0
NCT02416908 Phase Ib/II Selinexor Cladribine + Cytarabine + Plerixafor Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia Completed USA 0
NCT02418000 Phase Ib/II E6201 A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation Terminated USA 0
NCT02421939 Phase III Cytarabine Cytarabine + Fludarabine + Idarubicin Cytarabine + Etoposide + Mitoxantrone Azacitidine Gilteritinib Filgrastim A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation Active, not recruiting USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BEL 3
NCT02464657 Phase Ib/II Dexamethasone Cytarabine + Idarubicin + Nivolumab Nivolumab in Acute Myeloid Leukemia (AML) Completed USA 0
NCT02472145 Phase III Decitabine Decitabine + Talacotuzumab An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Completed USA | TUR | SWE | POL | ISR | GBR | FRA | ESP | DEU | BEL | AUS 3
NCT02485535 Phase I Selinexor Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Completed USA 0
NCT02487459 Phase I Rivogenlecleucel Rimiducid Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies Withdrawn USA 0
NCT02488408 Phase I Cytarabine Bemcentinib Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML Unknown status USA | NOR | ITA | DEU 0
NCT02494167 Phase I MultiTAA-specific T cells Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) Recruiting USA 0
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Completed USA 0
NCT02520011 Phase II Alvocidib Cytarabine + Mitoxantrone Alvocidib Biomarker-driven Phase 2 AML Study Terminated USA | GBR | ESP | CAN 0
NCT02520427 Phase I AMG 330 A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia Terminated USA | NLD | DEU | CAN 0
NCT02521493 Phase III Etoposide Thioguanine Cytarabine Asparaginase Erwinia chrysanthemi mitoxantrone hydrochloride Daunorubicin Asparaginase Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Active, not recruiting USA | NZL | CAN | AUS 2
NCT02527174 Phase I Cytarabine + Idarubicin + Volasertib A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC) Withdrawn CAN 0
NCT02528877 Phase I Fludarabine + Melphalan Ruxolitinib + Sirolimus + Tacrolimus Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis Withdrawn USA 0
NCT02530034 Phase I Hu8F4 Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Active, not recruiting USA 0
NCT02530476 Phase Ib/II Selinexor + Sorafenib Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia Completed USA 0
NCT02532010 Phase II Decitabine + Pacritinib Cytarabine + Pacritinib Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML Terminated USA 0
NCT02532231 Phase II Nivolumab Nivolumab in AML in Remission at High Risk for Relapse Completed USA 0
NCT02533115 Expanded access CPX-351 EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML Approved for marketing USA 0
NCT02543879 Phase I FT-1101 Azacitidine + FT-1101 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Completed USA 0
NCT02545283 Phase III Cytarabine Cytarabine + Idasanutlin A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia Terminated USA | NZL | NOR | NLD | ITA | ISR | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BEL | AUT | AUS 3
NCT02560025 Phase II Alisertib Daunorubicin Idarubicin Cytarabine Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML Completed USA 0
NCT02561455 Phase Ib/II Gilteritinib Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial Completed USA 0
NCT02573363 Phase I Cytarabine Mitoxantrone Selinexor Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed USA 0
NCT02576301 Phase Ib/II Combretastatin A1 Diphosphate Combretastatin A1 Diphosphate + Cytarabine Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS Unknown status USA 0
NCT02577406 Phase III Azacitidine Cytarabine Enasidenib An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY) Completed USA | TUR | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS 4
NCT02582359 Phase I Cytarabine + Daunorubicin + Ixazomib MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age Completed USA 0
NCT02583893 Phase II Cytarabine + Etoposide + Mitoxantrone + Sirolimus Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia Completed USA 0
NCT02610777 Phase II Azacitidine MLN4924 An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) Completed USA | NLD | ITA | ISR | IRL | FRA | ESP | DEU | CZE | CAN | BGR | BEL 0
NCT02624570 Phase I Midostaurin Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy. No longer available USA 0
NCT02626338 Phase Ib/II Crenolanib + Cytarabine + Mitoxantrone Pilot Study of Crenolanib Combined With Cytarabine and Mitoxantrone in Subjects With R/R AML Completed USA 0
NCT02632708 Phase I Enasidenib + Etoposide + Mitoxantrone Cytarabine + Enasidenib Cytarabine + Idarubicin + Ivosidenib Cytarabine + Daunorubicin + Enasidenib Cytarabine + Enasidenib + Idarubicin Etoposide + Ivosidenib + Mitoxantrone Cytarabine + Ivosidenib Cytarabine + Daunorubicin + Ivosidenib Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation Active, not recruiting USA | NLD | DEU 0
NCT02632721 Phase II BI 836858 + Decitabine Decitabine A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML) Completed USA | ITA | ESP | DEU 0
NCT02634827 Phase II Decitabine + Midostaurin Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation Terminated USA 0
NCT02635074 Phase I Cytarabine + Ibrutinib + Idarubicin Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Terminated USA 0
NCT02641002 Phase I CC-90002 A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) Terminated USA 0
NCT02642965 Phase Ib/II CPX-351 + Cytarabine + Filgrastim + Fludarabine Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed USA | CAN 0
NCT02649764 Phase I Cytarabine + Fludarabine + Prexasertib LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS) Completed USA 0
NCT02652871 Phase I Cytarabine + Idarubicin + LY2510924 A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed USA 0
NCT02665065 Phase III Fludarabine + Iomab-B Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML (SIERRA) Active, not recruiting USA | CAN 0
NCT02665143 Phase Ib/II Cytarabine + Idarubicin Nintedanib A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia Completed USA 0
NCT02666950 Phase II Adavosertib Cytarabine WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT02668653 Phase III Cytarabine + Daunorubicin + Idarubicin Cytarabine + Daunorubicin + Idarubicin + Quizartinib Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First) Completed USA | ROU | POL | ITA | ISR | HUN | HRV | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG 10
NCT02670044 Phase Ib/II Idasanutlin + Venetoclax Cobimetinib + Venetoclax A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy Completed USA | ITA | FRA | CAN 0
NCT02674763 Phase I IMGN779 Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia Completed USA 0
NCT02676323 Phase Ib/II Cytarabine + Fludarabine + Leucovorin + Panobinostat Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome Terminated USA 0
NCT02677922 Phase Ib/II Azacitidine + Ivosidenib Azacitidine Azacitidine + Enasidenib A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy Active, not recruiting USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS 2
NCT02680951 Phase I Cytarabine + Dasatinib + Fludarabine + Idarubicin Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia Withdrawn 0
NCT02683395 Phase I PLX51107 A Study of PLX51107 in Advanced Malignancies Terminated USA 0
NCT02684162 Phase II Guadecitabine SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT) Completed USA 0
NCT02698189 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005) Terminated 0
NCT02708641 Phase II Pembrolizumab A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients 60 With AML Completed USA 0
NCT02715011 Phase I JNJ-63709178 Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) Completed USA | ESP 0
NCT02717884 Phase Ib/II Cytarabine + Tranylcypromine + Tretinoin Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) (TRANSATRA) Unknown status DEU 0
NCT02719574 Phase I Cytarabine + Olutasidenib Olutasidenib Azacitidine + Olutasidenib Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 1
NCT02721875 Phase I Azacitidine Volasertib Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes Terminated 1
NCT02723435 Phase II Midostaurin Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant Withdrawn 0
NCT02724163 Phase III Gemtuzumab ozogamicin Busulfan + Fludarabine Cytarabine Cytarabine + Fludarabine Cytarabine + Daunoxome Busulfan + Cyclophosphamide Cytarabine + Mitoxantrone International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01) Recruiting NZL | IRL | GBR | FRA | CHE | AUS 0
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy in CBT Recruiting USA 0
NCT02728050 Phase Ib/II Sorafenib Cladribine + Cytarabine + Filgrastim + Mitoxantrone Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT02730312 Phase I Vibecotamab PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies Completed USA 0
NCT02743611 Phase I Rimiducid BPX-701 Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms Terminated USA 0
NCT02749708 Phase Ib/II IRX5183 Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Terminated USA 0
NCT02752035 Phase II Gilteritinib Azacitidine + Gilteritinib Azacitidine A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy Active, not recruiting USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT02756572 Phase I Sirolimus Mycophenolate mofetil Cyclosporine Cytarabine Melphalan Cladribine Filgrastim mitoxantrone hydrochloride Fludarabine Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed USA 0
NCT02756962 Phase II Midostaurin Cytarabine Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance Active, not recruiting USA 0
NCT02768792 Phase II Pembrolizumab High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML Completed USA 0
NCT02771197 Phase II Fludarabine + Melphalan Pembrolizumab Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant Completed USA 0
NCT02775903 Phase II Azacitidine Azacitidine + Durvalumab An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML) Completed USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 1
NCT02779283 Phase I Dasatinib Nilotinib Ponatinib Sorafenib Cytarabine + Idarubicin Sunitinib Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed USA 0
NCT02781883 Phase II BP1001 + Cytarabine Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With LDAC in Patients With Previously Untreated AML Recruiting USA 0
NCT02782546 Phase II Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation Recruiting USA 0
NCT02790515 Phase II Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim Provision of TCRgammadelta T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Active, not recruiting USA 0
NCT02791919 Phase I Adavosertib Cytarabine + Filgrastim + Fludarabine Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia Withdrawn 0
NCT02793544 Phase II Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Completed USA 0
NCT02795520 Phase Ib/II OTS167 Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Terminated USA 0
NCT02802267 Phase II Decitabine + Inecalcitol Decitabine Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy Unknown status USA | FRA 0
NCT02807558 Phase II Azacitidine + Tamibarotene Tamibarotene A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA | FRA 0
NCT02829840 Phase Ib/II Azacitidine + Ponatinib Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) Withdrawn 0
NCT02835222 Phase II Cytarabine + Daunorubicin + Selinexor Selinexor With Induction, Consolidation, and Maintenance Therapy in Treating Older Patients With Acute Myeloid Leukemia Recruiting USA 0
NCT02835729 Phase Ib/II Cytarabine + Idarubicin Cytarabine + Idarubicin + Indoximod A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Completed USA 0
NCT02841540 Phase I H3B-8800 A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Terminated USA | ITA | FRA | ESP | BEL 2
NCT02845297 Phase II Azacitidine + Pembrolizumab Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (?65 Years) AML Patients Completed USA 0
NCT02846376 Phase I Ipilimumab Ipilimumab + Nivolumab Nivolumab Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) Terminated USA 0
NCT02848001 Phase I CC-90009 A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes Terminated USA | NOR | GBR | FRA | ESP | CAN 0
NCT02848248 Phase I SGN-CD123A A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia Terminated USA 0
NCT02864290 Phase I AGS62P1 A Study to Evaluate Escalating Doses of AGS62P1 Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) Terminated USA | CAN 0
NCT02878785 Phase Ib/II Decitabine + Talazoparib Decitabine and Talazoparib in Untreated AML and R/R AML (1565GCC) Completed USA 0
NCT02882321 Phase I IACS-010759 Study of IACS-010759 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) Terminated USA 0
NCT02890329 Phase I Decitabine + Ipilimumab Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Active, not recruiting USA 0
NCT02890758 Phase I Nogapendekin alfa inbakicept Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Completed USA 0
NCT02892318 Phase I Atezolizumab + Guadecitabine A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) Completed USA 0
NCT02905994 Phase I Cytarabine + Idarubicin + Volasertib Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia Withdrawn USA 0
NCT02909972 Phase I ALRN-6924 + Cytarabine ALRN-6924 Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Completed USA 0
NCT02920008 Phase III Decitabine Azacitidine Cytarabine Guadecitabine Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia Completed USA | SWE | POL | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL 3
NCT02923986 Phase Ib/II BP1001 + Dasatinib Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS Withdrawn USA 0
NCT02927262 Phase III Gilteritinib A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission Completed USA | SWE | ROU | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA 5
NCT02930109 Phase Ib/II Cytarabine + Triciribine A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia Completed USA 0
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Terminated USA 0
NCT02936752 Phase I Entinostat + Pembrolizumab Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure Active, not recruiting USA 0
NCT02953561 Phase Ib/II Avelumab + Azacitidine Avelumab (antiPDL1) and Azacytidine in Acute Myeloid Leukemia (AML) Terminated USA 0
NCT02954653 Phase I PF-06747143 Cytarabine + Daunorubicin + PF-06747143 Azacitidine + Decitabine + PF-06747143 A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia Terminated USA 0
NCT02960646 Phase I Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed USA 0
NCT02979366 Phase I MIK665 Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome Completed USA | FRA | ESP | AUS 0
NCT02981914 Phase 0 Pembrolizumab Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation Completed USA 0
NCT02989844 Phase II Nogapendekin alfa inbakicept QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT Completed USA 0
NCT02993523 Phase III Azacitidine + Venetoclax Azacitidine A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Elderly Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy Active, not recruiting USA | TUR | SWE | POL | NOR | ITA | ISR | HUN | HRV | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS 9
NCT02996474 Phase Ib/II Decitabine + Pembrolizumab Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia Completed USA 0
NCT02997202 Phase III Gilteritinib A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) Completed USA | POL | NZL | ITA | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS 3
NCT03008187 Phase Ib/II SEL24-B489 SEL24 in Patients With AML Completed USA | POL | ITA | ESP 0
NCT03009240 Phase I Decitabine + MLN4924 Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03013998 Phase Ib/II Azacitidine + Enasidenib Azacitidine + Entospletinib Cytarabine + Daunorubicin + Samalizumab Azacitidine + BI 836858 Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Recruiting USA 0
NCT03017820 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Recruiting USA 0
NCT03018405 Phase Ib/II NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Unknown status USA | BEL 0
NCT03038230 Phase I MCLA-117 MCLA-117 in Acute Myelogenous Leukemia Unknown status USA | NLD | ITA | FRA | BEL 0
NCT03041688 Phase I Decitabine + KRT-232 + Venetoclax Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03042689 Phase I Regorafenib Study of Regorafenib in Patients With Advanced Myeloid Malignancies Completed USA 0
NCT03050216 Phase II Cyclophosphamide + Fludarabine + Nogapendekin alfa inbakicept Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML Completed USA 0
NCT03055286 Phase Ib/II CWP232291 + Cytarabine Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients Unknown status USA 1
NCT03059485 Phase II DC AML Vaccine DC AML Vaccine + Durvalumab DC/AML Fusion Cell Vaccine vs DC/AML Fusion Cell Vaccine Plus Durvalumab vs Observation in Patients Who Achieve a Chemotherapy-induced Remission Completed USA 0
NCT03063203 Phase II Decitabine Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Terminated USA 0
NCT03063944 Phase I Decitabine + OPB-111077 STAT Inhibitor OPB-111077 and Decitabine in Treating Patients With Acute Myeloid Leukemia That Is Refractory or Newly Diagnosed and Ineligible for Intensive Chemotherapy Completed USA 0
NCT03066648 Phase I Decitabine + Spartalizumab Decitabine + Sabatolimab + Spartalizumab Decitabine + Sabatolimab Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS Completed USA | NLD | GBR | FRA | FIN | ESP | DEU | AUS 0
NCT03067571 Phase II Daratumumab Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Terminated USA 0
NCT03069352 Phase III Cytarabine + Venetoclax Cytarabine A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy Active, not recruiting USA | NZL | NOR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG 8
NCT03069469 Phase I Vimseltinib Study of DCC-3014 in Patients With Advanced Malignancies Active, not recruiting USA | POL | NLD | ITA | GBR | FRA | ESP | CAN | AUS 0
NCT03070093 Expanded access Gilteritinib Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) Approved for marketing USA | CAN 1
NCT03071276 Phase II Cytarabine + Fludarabine + Methotrexate + Prednisone + Selinexor Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia Terminated USA 0
NCT03072043 Phase Ib/II APR-246 + Azacitidine Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms Completed USA 0
NCT03081780 Phase I FATE-NK100 Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML Completed USA 0
NCT03082209 Phase I ABBV-621 A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies Completed USA | NLD | ESP 1
NCT03092674 Phase II Cytarabine + Decitabine Azacitidine + Midostaurin Decitabine Azacitidine + Nivolumab Azacitidine Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Active, not recruiting USA 0
NCT03106428 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies Completed USA | FRA 1
NCT03110354 Phase I DS-3201b DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) Terminated USA 0
NCT03113643 Phase I Azacitidine + Tagraxofusp-erzs + Venetoclax Azacitidine + Tagraxofusp-erzs SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting USA 0
NCT03114228 Expanded access Midostaurin An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) No longer available CAN 0
NCT03125239 Phase I LY2874455 + Merestinib Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed USA 0
NCT03127735 Phase I BAY1436032 BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML) Completed USA | DEU 0
NCT03128034 Phase Ib/II Cyclosporine + Fludarabine + Mycophenolate mofetil + Sirolimus 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome Suspended USA 0
NCT03132454 Phase I Decitabine + Palbociclib Dexamethasone + Palbociclib Palbociclib Palbociclib + Sorafenib Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias Active, not recruiting USA 0
NCT03144245 Phase I AMV-564 Study of AMV564 in Patients With AML Completed USA 0
NCT03151408 Phase III Azacitidine Azacitidine + Pracinostat An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia Terminated USA | ROU | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | BRA | AUT | AUS | ARG 2
NCT03154827 Phase Ib/II Atezolizumab + BKT140 A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study Terminated USA | SVK | POL | ISR | ESP | CZE 0
NCT03164057 Phase II Etoposide Filgrastim Dexrazoxane Daunorubicin Idarubicin Fludarabine Asparaginase Cytarabine Sorafenib Mitoxantrone Decitabine Azacitidine A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03173248 Phase III Azacitidine Azacitidine + Ivosidenib Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE) Active, not recruiting USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUT | AUS 6
NCT03176277 Phase I ONO-7475 A Study of ONO-7475 in Patients With Acute Leukemias Terminated USA 0
NCT03187288 Phase I CFI-400945 A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed CAN 0
NCT03190278 Phase I UCART123 Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia Recruiting USA 0
NCT03194685 Phase Ib/II FF-10101 Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed USA 0
NCT03194932 Phase I Cytarabine Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed USA 0
NCT03207334 Phase II Cytarabine + Midostaurin iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-BMT-AML-001) Withdrawn USA 0
NCT03214562 Phase Ib/II Venetoclax Cytarabine + Filgrastim + Fludarabine + Idarubicin + Venetoclax Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) Recruiting USA 0
NCT03214666 Phase Ib/II GTB-3550 TriKE GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies Terminated USA 0
NCT03217838 Phase Ib/II AZD2811 Safety, Tolerability, and Efficacy of AZD2811 Nanoparticles in Patients With Relapsed AML/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients. Terminated USA | AUS 0
NCT03224819 Phase I AMG 673 Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia Terminated USA | DEU | AUS 0
NCT03226418 Phase II Cytarabine Decitabine + Venetoclax Azacitidine + Venetoclax CPX-351 Cytarabine + Idarubicin Azacitidine + Glasdegib Decitabine + Glasdegib Cytarabine, Idarubicin, Liposome-encapsulated Daunorubicin-Cytarabine or Decitabine in Treating Older Patients With Acute Myeloid Leukemia Completed USA 0
NCT03247088 Phase Ib/II Busulfan + Fludarabine + Sorafenib Cyclophosphamide Tacrolimus Filgrastim Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation Active, not recruiting USA 0
NCT03248479 Phase I Azacitidine + Hu5F9-G4 Hu5F9-G4 Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies Terminated USA | GBR 0
NCT03250338 Phase III Cytarabine + Filgrastim + Fludarabine + Idarubicin + Mitoxantrone Crenolanib + Cytarabine + Filgrastim + Fludarabine + Idarubicin + Mitoxantrone Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML Unknown status USA | ITA | FRA | ESP | DEU | CAN 0
NCT03263637 Phase I AZD4573 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Completed NLD | GBR | DEU 0
NCT03263936 Phase I Vorinostat Decitabine Cytarabine Fludarabine Filgrastim Epigenetic Reprogramming in Relapse/Refractory AML Completed USA | CAN | AUS 0
NCT03267186 Phase II Ibrutinib Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant Completed USA 0
NCT03286114 Phase I Pembrolizumab Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab Terminated USA 0
NCT03286530 Phase II Ruxolitinib Ruxolitinib + Allogeneic Stem Cell Transplantation in AML Recruiting USA 0
NCT03289910 Phase II Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Active, not recruiting USA 0
NCT03291353 Phase 0 Pembrolizumab Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia Withdrawn USA 0
NCT03298516 Phase I DCLL9718S Azacitidine + DCLL9718S A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy Completed USA | CAN 0
NCT03298984 Phase I Alvocidib + Cytarabine + Daunorubicin Ph I Study of Alvocidib and Cytarabine/Duanorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). Completed USA 0
NCT03303339 Phase Ib/II Decitabine + Onvansertib Cytarabine + Decitabine + Onvansertib Cytarabine + Onvansertib PCM-075 in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML). Completed USA 0
NCT03306264 Phase III Decitabine Decitabine and Cedazuridine Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML Completed USA | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | AUT 0
NCT03315039 Phase Ib/II Liposomal Annamycin Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) Completed USA 0
NCT03326921 Phase I Fludarabine HA-1 TCR T cells HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Suspended USA 0
NCT03330821 Phase Ib/II Cytarabine + Idarubicin + MLN4924 Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03335267 Phase II CPX-351 Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia Completed USA 0
NCT03358719 Phase I Decitabine + Nivolumab + Poly ICLC + Rasdegafusp alfa DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed USA 0
NCT03360006 Phase I ABBV-744 A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Advanced Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer Terminated USA 0
NCT03365661 Phase II Nogapendekin alfa inbakicept QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML Withdrawn USA 0
NCT03374332 Phase II Gemtuzumab ozogamicin Infusional Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Refractory Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03386513 Phase Ib/II IMGN632 Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 0
NCT03390296 Phase II Avelumab + Azacitidine + PF-04518600 Azacitidine + PF-04518600 Avelumab + Utomilumab Avelumab + Glasdegib Gemtuzumab ozogamicin + Glasdegib PF-04518600 Avelumab + PF-04518600 PF-04518600 + Utomilumab Pfizer Immunotherapy Combinations for Acute Myeloid Leukemia (AML) Multi-Arm Study 1 Completed USA 0
NCT03393611 Phase I anti-thymocyte globulin + Fludarabine + Melphalan CPX-351 CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT03395873 Phase I Avelumab + Decitabine Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy Terminated USA 0
NCT03397173 Phase II Azacitidine + Vitamin C TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid Completed USA 0
NCT03404193 Phase II Decitabine + Venetoclax Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome Active, not recruiting USA 0
NCT03404726 Phase I BAY2402234 A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies Terminated USA | FRA 0
NCT03412292 Phase I MAX-40279 MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) Unknown status AUS 0
NCT03416179 Phase III Cytarabine Cytarabine + Daunorubicin + Glasdegib Azacitidine + Glasdegib Azacitidine Cytarabine + Daunorubicin A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia (BRIGHT AML1019) Completed USA | SWE | ROU | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS 6
NCT03417154 Phase II Cyclophosphamide + Nivolumab Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS Completed USA 0
NCT03426605 Phase I LAM-003 A Study of LAM-003 in Patients With Acute Myeloid Leukemia Completed USA 0
NCT03441555 Phase I Alvocidib + Venetoclax A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Completed USA | GBR | DEU 0
NCT03451084 Phase II ASLAN003 A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia Completed USA | AUS 1
NCT03455504 Phase II Venetoclax Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia (V-FIRST) Active, not recruiting ITA 0
NCT03459859 Phase I Cytarabine + MLN4924 Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS Completed USA 0
NCT03465540 Phase I AMG 397 + Azacitidine AMG 397 + Dexamethasone AMG 397 Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies Terminated USA | ITA | GRC | FRA | AUS 1
NCT03466294 Phase II Azacitidine + Venetoclax Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML Active, not recruiting USA 0
NCT03471260 Phase Ib/II Azacitidine + Ivosidenib + Venetoclax Ivosidenib + Venetoclax Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies Recruiting USA 0
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Active, not recruiting USA 0
NCT03483324 Phase I AB-110 Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation Completed USA 0
NCT03484520 Phase I Dinaciclib + Venetoclax A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Terminated USA | ESP | AUS 0
NCT03503409 Phase II Ivosidenib IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome Active, not recruiting ITA | FRA 0
NCT03503968 Phase Ib/II MDG1011 TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms Terminated DEU 0
NCT03504410 Phase III Cytarabine + Mitoxantrone CPI-613 + Cytarabine + Mitoxantrone Study Evaluating Efficacy and Safety of CPI-613 in Combination With HD Cytarabine and Mitoxantrone vs HD Cytarabine and Mitoxantrone in Older Patients With R/R AML Terminated USA | POL | FRA | ESP | DEU | BEL | AUT | AUS 1
NCT03512197 Phase III Daunorubicin + Midostaurin Cytarabine + Idarubicin + Midostaurin Cytarabine + Idarubicin Daunorubicin A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) Completed USA | TUR | POL | NOR | ITA | ISR | FRA | ESP | DEU | CZE | CHE | BRA | BGR | BEL | AUT | AUS | ARG 3
NCT03513484 Phase I Azacitidine + Nintedanib Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03515512 Phase I Enasidenib IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Completed USA 0
NCT03526926 FDA approved CPX-351 A Post-Marketing Observational Study of VYXEOS Completed USA 0
NCT03531736 Phase I Rituximab Cyclophosphamide + Fludarabine T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia Active, not recruiting USA 0
NCT03531918 Phase Ib/II Cladribine + Cytarabine + Filgrastim + Gemtuzumab ozogamicin + Mitoxantrone Cladribine + Cytarabine + Filgrastim Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm Completed USA 0
NCT03537482 Phase I APG-2575 APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies Recruiting USA | AUS 0
NCT03537599 Phase Ib/II Daratumumab Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant Completed USA 0
NCT03541369 Phase I AMG 427 Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528) Terminated USA | DEU | CAN | AUS 2
NCT03552029 Phase I Milademetan + Quizartinib Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) Terminated USA 0
NCT03556228 Phase I VMD-928 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Recruiting USA 1
NCT03557970 Phase II Edicotinib CSF1R Inhibitor JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia Terminated USA 0
NCT03560882 Phase I Atorvastatin A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies Active, not recruiting USA 0
NCT03564288 Phase I SKI-G-801 Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML) Completed USA 0
NCT03564821 Phase I Ivosidenib IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Completed USA 0
NCT03568994 Phase I Atovaquone + Cytarabine + Daunorubicin + Etoposide Atovaquone + Cytarabine + Daunorubicin + Gemtuzumab ozogamicin Atovaquone (Mepron) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) Active, not recruiting USA 0
NCT03573024 Phase II Venetoclax Azacitidine Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03586609 Phase II Azacitidine + Cladribine + Cytarabine + Venetoclax Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Participants With Patients Previously Untreated Acute Myeloid Leukemia Recruiting USA 0
NCT03591510 Phase II Cytarabine Cytarabine + Etoposide Cytarabine + Mitoxantrone Cytarabine + Fludarabine + Idarubicin Cytarabine + Daunorubicin + Fludarabine Cytarabine + Daunoxome + Fludarabine Midostaurin A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML Recruiting USA | TUR | SVN | POL | ITA | GRC | DEU | CZE | AUT 4
NCT03594955 Phase Ib/II SAR440234 First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome Terminated USA | FRA 0
NCT03600155 Phase I Nivolumab Ipilimumab Ipilimumab + Nivolumab Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Participants With High Risk Refractory or Relapsed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03603964 Phase II Guadecitabine Guadecitabine Extension Study Terminated USA | ITA | ESP | DNK | CAN | AUT 3
NCT03613532 Phase I Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Recruiting USA 0
NCT03614728 Phase I Azacitidine + GSK3326595 GSK3326595 Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Terminated USA | CAN 0
NCT03616470 Phase III Cytarabine + Etoposide + Mitoxantrone + Uproleselan Cytarabine + Fludarabine + Idarubicin + Uproleselan Cytarabine + Etoposide + Mitoxantrone Cytarabine + Fludarabine + Idarubicin Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia Terminated USA | NLD | ITA | IRL | GBR | FRA | ESP | CAN | AUS 0
NCT03625505 Phase I Gilteritinib + Venetoclax A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia Completed USA 0
NCT03629171 Phase II CPX-351 + Venetoclax Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia Recruiting USA 0
NCT03634228 Phase Ib/II Cytarabine + Milademetan Cytarabine + Milademetan + Venetoclax Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia Terminated USA 0
NCT03661307 Phase Ib/II Decitabine + Quizartinib + Venetoclax Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Recruiting USA 0
NCT03670966 Phase Ib/II BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome Suspended USA 0
NCT03672539 Phase I Gemtuzumab ozogamicin CPX-351 + Gemtuzumab ozogamicin Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome Recruiting USA 0
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting USA 0
NCT03683433 Phase II Azacitidine + Enasidenib Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Recruiting USA 0
NCT03690115 Phase II Ponatinib Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients (PONALLO) Active, not recruiting FRA 0
NCT03699384 Phase Ib/II Avelumab + Azacitidine Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) Withdrawn USA 0
NCT03699475 Phase II Rimiducid + Rivogenlecleucel Cyclophosphamide Study of Haplo-HSCT + BPX-501 vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE) Terminated USA 0
NCT03701295 Phase Ib/II Azacitidine + Pinometostat Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement Completed USA 0
NCT03701308 Phase II Cytarabine + Daunorubicin Cytarabine + Uproleselan Cytarabine + Daunorubicin + Uproleselan Cytarabine Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy Active, not recruiting USA 0
NCT03709576 Phase II Azacitidine + MLN4924 Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML Terminated USA 0
NCT03709758 Phase I Cytarabine + Daunorubicin + Venetoclax Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naive AML Recruiting USA 0
NCT03724084 Phase Ib/II Cytarabine + Daunorubicin + Pinometostat Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement Terminated USA 0
NCT03728335 Phase I Enasidenib Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant Recruiting USA 0
NCT03730012 Phase Ib/II Atezolizumab + Gilteritinib A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) Completed USA 0
NCT03735446 Phase I Cytarabine + Etoposide + Mitoxantrone + Prexasertib Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial Terminated USA 0
NCT03735875 Phase Ib/II Quizartinib + Venetoclax Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia Terminated USA 0
NCT03737955 Phase II Gemtuzumab ozogamicin Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Participants With Acute Myeloid Leukemia Recruiting USA 0
NCT03745352 Phase II Azacitidine Azacitidine + MLN4924 Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Withdrawn 0
NCT03752138 Phase I Decitabine + TK216 TK216 TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia Withdrawn 0
NCT03755154 Phase I VOB560 Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia Terminated GBR | FRA | ESP | AUS 0
NCT03760523 Phase I Minnelide Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia Terminated USA 0
NCT03760666 Phase Ib/II Brequinar A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia Terminated USA 0
NCT03761069 Phase I PTC299 Study of PTC299 in Relapsed/Refractory Acute Leukemias Terminated USA 0
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Completed USA 0
NCT03772925 Phase I Belinostat + MLN4924 Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Active, not recruiting USA 0
NCT03787498 Phase I PLX2853 A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Completed USA 0
NCT03793478 Phase Ib/II Etoposide Cytarabine + Fludarabine + Methotrexate + Prednisolone + Quizartinib Cytarabine + Daunorubicin + Fludarabine + Methotrexate + Prednisolone + Quizartinib Cytarabine + Daunorubicin + Fludarabine + Hydrocortisone + Methotrexate + Quizartinib Cytarabine + Fludarabine + Methotrexate + Prednisolone Quizartinib Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood Active, not recruiting USA | SWE | NLD | ITA | ISR | FRA | ESP | DNK | CAN | BEL 0
NCT03797261 Phase I AMG 176 + Venetoclax A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies Terminated USA | DEU | AUS 0
NCT03807063 Phase I Rimiducid Rivogenlecleucel Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Withdrawn USA 0
NCT03813147 Phase I Azacitidine + Cytarabine + Fludarabine + MLN4924 Cytarabine Cytarabine + Hydrocortisone + Methotrexate Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome Completed USA 0
NCT03816319 Phase I TAK-243 TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts Recruiting USA 0
NCT03825796 Phase II CPX-351 + Enasidenib Cytarabine + Enasidenib Enasidenib CPX-351 Plus Enasidenib for Relapsed AML Active, not recruiting USA 0
NCT03826992 Phase I CPX-351 + Venetoclax Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia Recruiting USA 0
NCT03833180 Phase I VLS-101 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies Completed USA 0
NCT03836209 Phase II Cytarabine + Daunorubicin + Gilteritinib Cytarabine + Daunorubicin + Midostaurin Cytarabine Midostaurin Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03839446 Phase II Etoposide + Gemtuzumab ozogamicin + Mitoxantrone Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy Active, not recruiting USA 0
NCT03839771 Phase III Ivosidenib Enasidenib A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML) Active, not recruiting SWE | NOR | NLD | LUX | LTU | IRL | FRA | FIN | EST | ESP | DEU | CHE | BEL | AUT | AUS 0
NCT03843528 Phase I Azacitidine + Vorinostat Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation Recruiting USA 0
NCT03844815 Phase I Decitabine + Venetoclax Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03844997 Phase I CPX-351 + Palbociclib Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia Completed USA 0
NCT03848754 Phase I Gemtuzumab ozogamicin + Pracinostat Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Completed USA 0
NCT03850535 Phase Ib/II Cytarabine + Idasanutlin Cytarabine + Daunorubicin + Idasanutlin Idasanutlin A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission Terminated USA | ITA | FRA | ESP | AUS 0
NCT03850574 Phase Ib/II Tuspetinib + Venetoclax Tuspetinib Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (APTIVATE) Recruiting USA | NZL | ESP | DEU | AUS 1
NCT03860844 Phase II Idarubicin Cyclophosphamide Isatuximab Doxorubicin Etoposide Daunoxome Cytarabine Methotrexate Daunorubicin Fludarabine Dexamethasone Mitoxantrone Filgrastim Vincristine Sulfate Pegaspargase Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Terminated USA | SWE | NOR | NLD | ITA | HUN | GRC | FRA | DNK | DEU | BRA | ARG 4
NCT03862157 Phase Ib/II Azacitidine + MLN4924 + Venetoclax Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03874052 Phase I Ruxolitinib + Venetoclax Ruxolitinib in Combination With Venetoclax for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Suspended USA 0
NCT03878199 Phase Ib/II CPX-351 + Ruxolitinib Cytarabine and Daunorubicin in Combination With Ruxolitinib for the Treatment of Secondary Acute Myeloid Leukemia Transformed From Myeloproliferative Neoplasms. Recruiting USA 0
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Terminated USA 0
NCT03878927 Phase I CPX-351 + Gemtuzumab ozogamicin CPX-351+GO in Subjects 55 Years Old, or Older, With AML (CPX GO) Terminated USA 0
NCT03881735 Phase II Enasidenib Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation Withdrawn USA 0
NCT03885947 Phase I Cyclophosphamide + Fludarabine + Thiotepa VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies Completed USA 0
NCT03900949 Phase I Midostaurin Cytarabine Cytarabine + Gemtuzumab ozogamicin Cytarabine + Daunorubicin + Gemtuzumab ozogamicin Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia Recruiting USA 0
NCT03904069 Phase I Anti-FLT3 CAR-T cells Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML Withdrawn USA 0
NCT03904251 Phase I CPX-351 + Gemtuzumab ozogamicin CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia Terminated USA 0
NCT03912064 Phase I Ipilimumab A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Active, not recruiting USA 0
NCT03913026 Phase II ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia Active, not recruiting CAN 0
NCT03915379 Phase I JNJ-67571244 A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Completed USA | ESP | DEU 0
NCT03922100 Phase Ib/II NMS-P088 Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML Terminated ITA | FRA | ESP 0
NCT03922477 Phase I Atezolizumab + Hu5F9-G4 A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia Terminated USA 0
NCT03926624 Phase III Decitabine + Venetoclax Azacitidine + Venetoclax Cytarabine + Filgrastim + Fludarabine + Idarubicin Cytarabine + Venetoclax Cytarabine + Filgrastim + Fludarabine Decitabine Azacitidine Cladribine + Cytarabine + Filgrastim + Mitoxantrone DFP-10917 Cladribine + Cytarabine + Filgrastim + Idarubicin Cytarabine Cytarabine + Etoposide + Mitoxantrone Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage Unknown status USA 0
NCT03927261 Phase I PRGN-3006 PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS Active, not recruiting USA 0
NCT03931291 Phase II APR-246 + Azacitidine APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant Completed USA 0
NCT03932643 Phase I ONC201 ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant Active, not recruiting USA 0
NCT03934372 Phase Ib/II Ponatinib Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Recruiting SWE | NLD | ITA | GBR | FRA | ESP | DNK | DEU | BEL 0
NCT03940352 Phase I Siremadlin + Venetoclax Sabatolimab + Siremadlin HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) Terminated USA | ITA | FIN | ESP | DEU | AUS 1
NCT03941964 Phase III Decitabine + Venetoclax Azacitidine + Venetoclax A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Completed USA 0
NCT03953898 Phase II Olaparib Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation Active, not recruiting USA 0
NCT03955783 Phase I Selinexor + Venetoclax Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies Completed USA 0
NCT03957915 Phase I INA03 Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (INA03) Recruiting FRA 0
NCT03969420 Phase II Alvocidib + Cytarabine Alvocidib Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy Terminated USA 0
NCT03969446 Phase I Decitabine + Pembrolizumab Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory Recruiting USA 0
NCT03971799 Phase Ib/II Cyclophosphamide + Fludarabine Anti-CD33 CAR-T cells Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT03974217 Phase I Talazoparib Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts Recruiting USA 0
NCT03983824 Phase I Cytarabine + Etoposide + Mitoxantrone + Peposertib Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT03988205 FDA approved CPX-351 Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia Terminated USA 0
NCT04013880 Phase Ib/II Decitabine and Cedazuridine + Olutasidenib ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Withdrawn 0
NCT04021368 Phase I RVU120 SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Active, not recruiting USA | POL 0
NCT04022785 Phase I Azacitidine + PLX51107 PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT04023071 Phase I Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Obinutuzumab Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Rituximab Aldesleukin + Cyclophosphamide + Fludarabine + FT516 FT516 in Subjects With Advanced Hematologic Malignancies Terminated USA 0
NCT04023526 Phase II ARGX-110 + Azacitidine A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (CULMINATE) Active, not recruiting TUR | ITA | ISR | FRA | ESP | CHE | BRA | AUS 1
NCT04027309 Phase III Midostaurin Gilteritinib A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML) Active, not recruiting SWE | NOR | NLD | LUX | LTU | IRL | FRA | FIN | ESP | DEU | CHE | BEL | AUT | AUS 0
NCT04029688 Phase Ib/II Idasanutlin + Venetoclax Cyclophosphamide + Idasanutlin + Topotecan Cytarabine + Fludarabine + Idasanutlin Cytarabine + Hydrocortisone + Methotrexate Cytarabine Methotrexate Idasanutlin Cyclophosphamide + Idasanutlin A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors Completed USA | NLD | GBR | FRA | ESP | CAN 0
NCT04047641 Phase II Quizartinib Cladribine + Cytarabine + Idarubicin + Quizartinib Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04049539 Phase II CPX-351 Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction Recruiting USA 0
NCT04050280 Phase II Cladribine + Cytarabine + Filgrastim + Gemtuzumab ozogamicin Gemtuzumab ozogamicin Cladribine + Cytarabine + Filgrastim CLAG-GO for Patients With Persistent, Relapsed or Refractory AML Recruiting USA 0
NCT04051996 Phase II Decitabine + Glasdegib GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia Terminated USA 0
NCT04055844 Phase II Decitabine + Ruxolitinib Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS Completed USA 0
NCT04062266 Phase II Azacitidine + Venetoclax AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission Recruiting USA 0
NCT04065399 Phase Ib/II Revumenib A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) Recruiting USA | NLD | LTU | ITA | ISR | FRA | ESP | DEU | CAN | AUS 1
NCT04067336 Phase I Ziftomenib First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 0
NCT04068597 Phase Ib/II CCS1477 Study to Evaluate CCS1477 in Haematological Malignancies Recruiting USA | SWE | GBR | FRA | ESP 0
NCT04070768 Phase I Gemtuzumab ozogamicin + Venetoclax Venetoclax Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Active, not recruiting USA 0
NCT04075747 Phase I CPX-351 + Enasidenib CPX-351 + Venetoclax CPX-351 + Midostaurin A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia (V-FAST) Completed USA 0
NCT04079296 Phase Ib/II ASP7517 A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) Completed USA 1
NCT04079738 Phase Ib/II Ixazomib + Mivavotinib Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib Terminated USA 0
NCT04081259 Phase I LY3214996 LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy Recruiting USA 0
NCT04086264 Phase Ib/II IMGN632 IMGN632 + Venetoclax Azacitidine + IMGN632 Azacitidine + IMGN632 + Venetoclax IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 0
NCT04090736 Phase III Azacitidine Azacitidine + MLN4924 Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy (PEVOLAM) Unknown status ESP 1
NCT04092179 Phase Ib/II Enasidenib + Venetoclax Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Terminated CAN 0
NCT04093505 Phase III Gemtuzumab ozogamicin + Glasdegib Gemtuzumab ozogamicin Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) (GnG) Terminated DEU 0
NCT04102020 Phase III Azacitidine + Venetoclax A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival (VIALE-M) Active, not recruiting USA | TUR | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | AUS 6
NCT04103879 Phase II ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia Active, not recruiting USA | NLD 0
NCT04107727 Phase II Cytarabine Cytarabine + Idarubicin Cytarabine + Idarubicin + Quizartinib Quizartinib Cytarabine + Quizartinib Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Unknown status ESP 0
NCT04109482 Phase Ib/II Cyclophosphamide + Decitabine + Fludarabine + MB-102 Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN, AML, and hrMDS. Terminated USA 0
NCT04112589 Phase Ib/II Cytarabine + Fludarabine + Idarubicin + Lenograstim + Quizartinib Lenograstim A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment Unknown status ESP 0
NCT04113616 Phase Ib/II KRT-232 Decitabine + KRT-232 Cytarabine + KRT-232 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) Terminated USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | BEL | AUS 1
NCT04128020 Phase I Azacitidine + Nivolumab Nivolumab Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia Withdrawn 0
NCT04128501 Phase II Azacitidine + Venetoclax Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting Recruiting USA 0
NCT04128748 Phase Ib/II CPX-351 + Quizartinib Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04139434 Phase I LP-108 Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) Active, not recruiting USA | ESP 0
NCT04140487 Phase Ib/II Azacitidine + Gilteritinib + Venetoclax Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm Recruiting USA 0
NCT04146038 Phase II Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Completed USA 0
NCT04150029 Phase II Azacitidine + Sabatolimab + Venetoclax A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (STIMULUS-AML1) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | AUS 3
NCT04150887 Phase I ARGX-110 + Azacitidine + Venetoclax ARGX-110 + Venetoclax ARGX-110 + Azacitidine Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (ELEVATE) Active, not recruiting USA | POL | DEU | CHE | CAN 0
NCT04155580 Phase I ASTX-660 ASTX-660 + Decitabine and Cedazuridine A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) Terminated USA 0
NCT04158739 Phase I Cytarabine + Flotetuzumab Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04161885 Phase III Azacitidine + Venetoclax A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T) Active, not recruiting USA | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | AUS 4
NCT04167696 Phase I CYAD-02 Cyclophosphamide + Fludarabine Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1) Recruiting USA | BEL 0
NCT04167917 Phase I NTX-301 NTX-301 in MDS/AML Recruiting USA 0
NCT04168502 Phase III Gemtuzumab ozogamicin + Glasdegib Gemtuzumab ozogamicin Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML Recruiting ITA 0
NCT04172844 Phase I Azacitidine + MLN4924 + Venetoclax Pevonedistat, Azacitidine, and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia (PAVE) Terminated USA 0
NCT04173585 Phase II Bortezomib + Gemtuzumab ozogamicin TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib (TEAM) Completed DEU 0
NCT04188405 Phase II Decitabine + Ponatinib + Venetoclax Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia Active, not recruiting USA 0
NCT04190550 Phase I Cytarabine + Idarubicin + KRT-232 Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04195945 Phase II CPX-351 Cladribine + Cytarabine + Filgrastim + Mitoxantrone CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients Recruiting USA 0
NCT04203316 Phase II Enasidenib Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation Recruiting USA | CAN 0
NCT04207190 Phase Ib/II Gemtuzumab ozogamicin + Talazoparib Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia Completed USA 0
NCT04209725 Phase II CPX-351 + Quizartinib A Study of CPX-351 (Vyxeos) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia Terminated USA 0
NCT04214249 Phase II Cytarabine + Daunorubicin Cytarabine Cytarabine + Idarubicin Pembrolizumab Cytarabine + Daunorubicin + Pembrolizumab Cytarabine + Pembrolizumab Cytarabine + Idarubicin + Pembrolizumab BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04214860 Phase I APR-246 + Azacitidine + Venetoclax APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies Completed USA 0
NCT04219163 Phase I CLL-1 CAR-T cells Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen Recruiting USA 0
NCT04227847 Phase I SEA-CD70 A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies Recruiting USA | NLD 0
NCT04229979 Phase III Galinpepimut-S Cytarabine Decitabine Venetoclax Azacitidine Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (REGAL) Active, not recruiting USA | POL | HUN | GRC | FRA | ESP | DEU 3
NCT04231851 Phase II CPX-351 + Glasdegib CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04240002 Phase Ib/II Cytarabine + Filgrastim + Fludarabine + Gilteritinib A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 0
NCT04243499 Phase I ICT01 First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) Recruiting USA | GBR | FRA | ESP | DEU | BEL 0
NCT04243785 Phase I BTX-A51 A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04250051 Phase I Cytarabine + Filgrastim + Fludarabine + Ivosidenib Ivosidenib Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT04256317 Phase III ASTX030 ASTX030 + Azacitidine ASTX030 + Azacitidine + Cedazuridine A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML Active, not recruiting USA | CAN 0
NCT04266795 Phase II Azacitidine + Venetoclax Azacitidine + MLN4924 + Venetoclax A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy (PEVENAZA) Active, not recruiting USA | POL | ITA | FRA | CAN 0
NCT04272203 Phase I ABBV-184 A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers Terminated USA | ISR | GBR | FRA 1
NCT04277442 Phase I Decitabine + Nivolumab + Venetoclax Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04278768 Phase I CA-4948 An Open Label Dose Escalation Trial of CA-4948 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Recruiting USA | POL | ITA | ISR | FRA | ESP | DEU | CZE 0
NCT04282668 Phase I TAS1440 + Tretinoin TAS1440 A Study of TAS1440 With ATRA in Subjects With r/r AML Active, not recruiting USA 0
NCT04284228 Phase Ib/II Cyclophosphamide + Fludarabine + NEXI-001 T Cells Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT Active, not recruiting USA 0
NCT04284787 Phase II Azacitidine + Pembrolizumab + Venetoclax Azacitidine + Venetoclax BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04310592 Phase I Cyclophosphamide + Fludarabine CYNK-001 Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01) Recruiting USA 0
NCT04318678 Phase I Cyclophosphamide + Fludarabine + MB-102 + Mesna + Rituximab CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) Recruiting USA 0
NCT04326439 Phase II Cytarabine + Etoposide Cytarabine + Etoposide + Sorafenib Asparaginase Erwinia chrysanthemi + Cytarabine + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin + Sorafenib Cytarabine + Mitoxantrone + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin Asparaginase Erwinia chrysanthemi + Cytarabine Cytarabine + Mitoxantrone AflacLL1901 (CHOA-AML) Terminated USA 0
NCT04326764 Phase III Panobinostat Panobinostat Maintenance After HSCT fo High-risk AML and MDS Terminated NLD | DEU 0
NCT04336982 Phase Ib/II Azacitidine + CC-90009 + Venetoclax CC-90009 + Gilteritinib A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia Terminated USA | GBR | FRA | CAN | BEL 0
NCT04358393 Phase Ib/II Alrizomadlin + Azacitidine Alrizomadlin A Study of APG-115 Alone or in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) Recruiting USA 0
NCT04361058 Phase I Nivolumab Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide Withdrawn USA 0
NCT04372433 Phase I Azacitidine + IO-202 IO-202 Azacitidine + IO-202 + Venetoclax IO-202 as Monotherapy and IO-202 Plus Azacitidine +/- Venetoclax in Patients in AML and CMML Active, not recruiting USA 0
NCT04385290 Phase Ib/II Cytarabine + Daunorubicin + Gemtuzumab ozogamicin + Midostaurin Cytarabine + Daunorubicin + Gemtuzumab ozogamicin Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) (MOSAIC) Recruiting DEU 0
NCT04402541 Phase I CB-5339 Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA | AUS 0
NCT04429191 Phase I JSP191 JSP191 Antibody Targeting Conditioning in MDS/AML Patients Undergoing Hematopoietic Cell Transplantation Unknown status USA 0
NCT04435691 Phase Ib/II Azacitidine + Hu5F9-G4 + Venetoclax Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04477291 Phase Ib/II CG-806 A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04478695 Phase I AMG 330 + Pembrolizumab Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia Terminated USA 0
NCT04487106 Phase II Azacitidine + Trametinib + Venetoclax Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome Completed USA 0
NCT04493099 Phase Ib/II Alvocidib + Decitabine + Venetoclax Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML Withdrawn USA 0
NCT04493164 Phase II CPX-351 + Ivosidenib Ivosidenib CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04500587 Phase I ZN-d5 Phase 1 First in Human Study of ZN-d5 as a Single Agent Completed POL | HRV | ESP | BGR | AUS 2
NCT04511130 Phase II MT-401 Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant Completed USA 0
NCT04512105 Phase I Azacitidine + Pitavastatin + Venetoclax Decitabine + Pitavastatin + Venetoclax Pitavastatin + Venetoclax Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04518345 Phase Ib/II Dubermatinib Azacitidine + Dubermatinib TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia Completed USA 0
NCT04522895 Phase II Enasidenib IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT Completed DEU 0
NCT04526795 Phase I Cytarabine + Fludarabine + Pegcrisantaspase Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Active, not recruiting USA 0
NCT04543305 Phase I PRT1419 A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies Completed USA 0
NCT04547062 Phase I Tocilizumab Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML) (Tocilam) Completed FRA 0
NCT04580121 Phase I Dasatinib + RO7283420 + Tocilizumab A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. Completed USA | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUS 1
NCT04581512 Phase Ib/II EP0042 Study to Evaluate the Safety and Tolerability of EP0042 Recruiting NLD | GBR | AUS 0
NCT04582864 Phase II Flotetuzumab Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Terminated USA 0
NCT04588922 Phase I GFH009 A Study of GFH009 in Patients With Hematologic Malignancies Recruiting USA 1
NCT04609826 Phase I JNJ74856665 Azacitidine + JNJ74856665 JNJ74856665 + Venetoclax A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Active, not recruiting GBR | FRA | ESP 1
NCT04614636 Phase I Cyclophosphamide + Fludarabine Daratumumab + FT538 Elotuzumab + FT538 FT538 FT538 in Subjects With Advanced Hematologic Malignancies Terminated USA 0
NCT04623216 Phase Ib/II Sabatolimab Azacitidine + Sabatolimab Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. Completed ITA | FRA | ESP | DEU 0
NCT04628026 Phase III Cytarabine + Idarubicin + Venetoclax Cytarabine + Idarubicin Etoposide + Mitoxantrone + Venetoclax Etoposide + Mitoxantrone Cytarabine + Venetoclax Cytarabine + Daunorubicin + Venetoclax Cytarabine + Daunorubicin Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 Recruiting DEU 0
NCT04629443 Phase Ib/II Azacitidine + MIK665 Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia Completed USA | FRA | ESP | AUS 0
NCT04637009 Phase I TAS1553 A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms Terminated USA | CAN 0
NCT04639024 Phase II Camidanlumab tesirine ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN Terminated USA 0
NCT04655391 Phase I Glasdegib Glasdegib + Ivosidenib Bosutinib + Glasdegib Gilteritinib + Glasdegib Decitabine + Glasdegib + Venetoclax Enasidenib + Glasdegib Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation Withdrawn USA 0
NCT04657081 Phase I Decitabine and Cedazuridine + Venetoclax Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) Active, not recruiting USA | ESP | CAN 0
NCT04659616 Phase I Cytarabine + Pemigatinib Cytarabine + Daunorubicin + Pemigatinib Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia Recruiting USA 0
NCT04666649 Phase I Pegcrisantaspase + Venetoclax Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Active, not recruiting USA 0
NCT04669067 Phase Ib/II KRT-232 + TL-895 TL-895 and KRT-232 Study in Acute Myeloid Leukemia Active, not recruiting USA | ITA | FRA | ESP | DEU | AUT | AUS 1
NCT04678336 Phase I CART123 cells Cyclophosphamide + Fludarabine CD123 Redirected T Cells for AML in Pediatric Subjects Recruiting USA 0
NCT04687761 Phase Ib/II Cytarabine + Quizartinib + Venetoclax Azacitidine + Quizartinib + Venetoclax Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old Unknown status ESP 0
NCT04702425 Phase I MIK665 + VOB560 VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) Terminated USA | ITA | ISR | FIN | ESP | BEL 3
NCT04708054 Phase II Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS Recruiting USA 0
NCT04712942 Phase II Azacitidine + MLN4924 Azacitidine Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat Completed DEU 0
NCT04714372 Phase I Cyclophosphamide + Fludarabine Daratumumab and hyaluronidase-fihj + FT538 FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia Completed USA 0
NCT04730258 Phase Ib/II CFI-400945 CFI-400945 + Decitabine Azacitidine + CFI-400945 A Study of CFI-400945 With or Without Azacitidine or Decitabine in Patients With AML, MDS or CMML (TWT-202) Recruiting USA | CAN 1
NCT04742101 Phase Ib/II Azacitidine + VOB560 Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia Active, not recruiting POL | HUN | GBR | FRA | ESP 1
NCT04746235 Phase II Decitabine and Cedazuridine + Venetoclax Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia Recruiting USA 0
NCT04748848 Phase Ib/II Azacitidine + Venetoclax Azacitidine + CC-90011 + Venetoclax A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy Terminated USA | FRA | ESP | BEL 0
NCT04752163 Phase Ib/II Cyclophosphamide + Cytarabine + Dexamethasone + DS-1594b + Filgrastim + Mesna + Methotrexate + Vincristine Sulfate DS-1594b + Prednisone + Vincristine Sulfate DS-1594b Azacitidine + DS-1594b + Venetoclax Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate + Rituximab DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Completed USA 0
NCT04755244 Phase Ib/II Azacitidine + Evorpacept + Venetoclax A Study of ALX148 With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) Terminated USA 0
NCT04771130 Phase Ib/II Azacitidine + BGB-11417 A Study of BGB-11417 in Participants With Myeloid Malignancies Recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | AUS 2
NCT04771572 Phase I LP-118 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. Recruiting USA 0
NCT04774393 Phase Ib/II Decitabine and Cedazuridine + Ivosidenib + Venetoclax Decitabine and Cedazuridine + Enasidenib + Venetoclax Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT04778397 Phase III Cytarabine + Idarubicin Azacitidine + Venetoclax Azacitidine + Hu5F9-G4 Cytarabine + Daunorubicin Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated (ENHANCE-2) Terminated USA | SWE | ITA | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BEL | AUT | AUS 2
NCT04778410 Phase II Azacitidine + Hu5F9-G4 + Venetoclax Cytarabine + Etoposide + Hu5F9-G4 + Mitoxantrone Azacitidine + Hu5F9-G4 Study of Magrolimab Combinations in Participants With Myeloid Malignancies Completed USA | GBR | AUS 0
NCT04789408 Phase I Cyclophosphamide + Fludarabine + KITE-222 Study Evaluating the Safety of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia Terminated USA | FRA 0
NCT04789655 Phase I CC-96191 Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia Recruiting USA | FRA | CAN 0
NCT04797767 Phase I Cladribine + Cytarabine + Mitoxantrone + Sargramostim + Venetoclax Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms Suspended USA 0
NCT04801797 Phase II Azacitidine + Venetoclax Cytarabine + Idarubicin Cytarabine + Daunoxome Cytarabine + Daunorubicin Venetoclax + Azacitidine vs. Induction Chemotherapy in AML Recruiting USA 0
NCT04817241 Phase Ib/II Cytarabine + Daunorubicin Decitabine and Cedazuridine + Venetoclax Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients Active, not recruiting USA 0
NCT04848974 Phase Ib/II Cladribine + Cytarabine + Uproleselan Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia Completed USA 0
NCT04865419 Phase Ib/II AZD0466 + Voriconazole AZD0466 Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies Terminated USA | ITA | FRA | DEU | AUS 1
NCT04872478 Phase I MRX-2843 Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL Recruiting USA 0
NCT04874194 Phase Ib/II Omacetaxine mepesuccinate + Venetoclax Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 Completed USA 0
NCT04874480 Phase I BC2059 + Decitabine Tegavivint for the Treatment of Relapsed or Refractory Leukemia Active, not recruiting USA 0
NCT04887857 Phase I Azacitidine + Venetoclax A Study to Assess Safety and Tolerability of CC-486 (ONUREG, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) (OMNIVERSE) Completed USA | AUS 0
NCT04891757 Phase I FHD-286 FHD-286 in Subjects With Advanced Hematologic Malignancies Recruiting USA 0
NCT04898894 Phase I Cytarabine + Filgrastim + Fludarabine + Methotrexate + Selinexor + Venetoclax Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Recruiting USA 0
NCT04905810 Phase II Azacitidine + Decitabine + Venetoclax Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure Recruiting USA 0
NCT04912063 Phase I Azacitidine + Lemzoparlimab Azacitidine + Lemzoparlimab + Venetoclax Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitdine With or Without Venetoclax in Participants With Myelodysplastic Syndrome Terminated USA | ITA | ISR | ESP | DEU | AUS 1
NCT04913922 Phase II Azacitidine + Nivolumab + Relatlimab Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML (AARON) Recruiting DEU 0
NCT04914845 Phase I KPT-9274 KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT04915612 Phase I CPX-351 + Gemtuzumab ozogamicin Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04926285 Phase I Omacetaxine mepesuccinate + Venetoclax Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Recruiting USA 0
NCT04937166 Phase I Azacitidine + DSP107 + Venetoclax A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies Recruiting USA 0
NCT04951778 Phase I CC-91633 Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes Recruiting USA | GBR | ESP | CAN | AUS 0
NCT04953780 Phase I Calaspargase pegol-mknl + Cytarabine + Idarubicin 2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML Active, not recruiting USA 0
NCT04964505 Phase I Azacitidine + Uproleselan + Venetoclax Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04964518 Phase I APG-2575 + Azacitidine A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) Recruiting USA | AUS 0
NCT04975919 Phase II Decitabine and Cedazuridine + Venetoclax Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04982354 Phase Ib/II Busulfan + CPX-351 + Fludarabine + Melphalan + Midostaurin Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia Withdrawn USA 0
NCT04988555 Phase Ib/II DSP-5336 A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation Recruiting USA | ITA | FRA | ESP | CAN | BEL 4
NCT05010122 Phase Ib/II Decitabine and Cedazuridine + Gilteritinib + Venetoclax ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT05010772 Phase I Decitabine and Cedazuridine Decitabine and Cedazuridine + Ivosidenib Decitabine and Cedazuridine + Gilteritinib Decitabine and Cedazuridine + Enasidenib Decitabine and Cedazuridine + Venetoclax Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission Recruiting USA 0
NCT05020665 Phase III Anthracycline + Cytarabine Anthracycline + Cytarabine + Entospletinib A Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia Terminated USA | POL | ITA | ISR | HUN | FRA | ESP | DEU | CZE | CAN | BRA 1
NCT05024552 Phase I CPX-351 + Gilteritinib Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML Recruiting USA 0
NCT05024994 Phase II E7820 A Study of E7820 in People With Bone Marrow (Myeloid) Cancers Active, not recruiting USA 0
NCT05028751 Phase Ib/II Gilteritinib + Lanraplenib A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Terminated USA | ESP 0
NCT05038644 Phase I XmAb18968 XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia Active, not recruiting USA 0
NCT05038800 Phase I MK-0482 A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) (MK-0482-002) Terminated USA | ISR | ESP 0
NCT05079230 Phase III Azacitidine + Hu5F9-G4 + Venetoclax Azacitidine + Venetoclax Study Evaluating the Safety and Effectiveness Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia (AML) (ENHANCE-3) Terminated USA | POL | NOR | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS 3
NCT05086315 Phase Ib/II SAR443579 First-in-human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) Recruiting USA | NLD | FRA | AUS 1
NCT05107856 Phase I PRT1419 A Study of PRT1419 Injection in Patients With Relapsed/Refractory Hematologic Malignancies Terminated USA 0
NCT05143996 Phase I CLN-049 CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) Recruiting USA 0
NCT05144334 Phase I BTX-1188 A Study of BTX-1188 in Subjects With Advanced Malignancies Terminated USA 0
NCT05146739 Phase I Cytarabine + Fludarabine + Uproleselan Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane Active, not recruiting USA 0
NCT05155709 Phase Ib/II Azacitidine + Siremadlin + Venetoclax A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. Completed USA | TUR | ITA | ISR | HUN 2
NCT05168202 Phase I Azacitidine + CC-95251 CC-95251 A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes Completed USA | SWE | NOR | ITA | GBR | FRA | ESP | CAN | AUS 0
NCT05168904 Phase Ib/II CYC065 A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) Suspended USA 0
NCT05183035 Phase III Azacitidine + Cytarabine + Fludarabine + Gemtuzumab ozogamicin + Venetoclax Azacitidine + Cytarabine + Fludarabine + Gemtuzumab ozogamicin Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) Recruiting USA | SWE | NZL | NOR | NLD | ITA | ISR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BEL | AUT | AUS 1
NCT05188170 Phase I Niclosamide Phase 1 Study of Niclosamide in Pediatric Patients With Relapsed and Refractory AML Recruiting USA 0
NCT05190471 Phase I BP1002 + Decitabine BP1002 A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) Unknown status USA 0
NCT05222984 Phase I Decitabine + Navitoclax + Venetoclax Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax Active, not recruiting USA 0
NCT05263284 Phase I 8-Chloroadenosine + Venetoclax 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia Suspended USA 0
NCT05275439 Phase I Azacitidine + SL-172154 + Venetoclax Azacitidine + SL-172154 SL-172154 Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML Active, not recruiting USA | GBR | CAN 0
NCT05279859 Phase Ib/II ERAS-007 + Gilteritinib A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies (HERKULES-4) Withdrawn USA 0
NCT05287568 Phase I Azacitidine + Venetoclax CC-486 and Venetoclax for Acute Myeloid Leukemia Recruiting USA 0
NCT05292664 Phase I Azacitidine + Cytarabine + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax Calaspargase pegol-mknl + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax + Vincristine Sulfate Azacitidine + Venetoclax Venetoclax Basket Trial for High Risk Hematologic Malignancies Recruiting USA 0
NCT05317403 Phase I Azacitidine + Cytarabine + Filgrastim + Fludarabine + Venetoclax + Vorinostat Venetoclax to Augment Epigenetic Modification and Chemotherapy Recruiting USA 0
NCT05326516 Phase I Revumenib A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia Completed USA | CAN 0
NCT05330377 Phase I Cladribine + Cytarabine + Filgrastim + Gilteritinib + Mitoxantrone GM-CLAG in Relapsed/Refractory FLT3-mutated AML Withdrawn USA 0
NCT05342584 Phase I Cytarabine + Daunorubicin + Venetoclax Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS Recruiting USA 0
NCT05360160 Phase Ib/II Decitabine and Cedazuridine Revumenib Venetoclax A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) Recruiting USA 0
NCT05362773 Phase I MGD024 A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies Recruiting USA 0
NCT05377827 Phase I WU-CART-007 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies Active, not recruiting USA 0
NCT05396859 Phase I Decitabine and Cedazuridine + Entrectinib Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia Recruiting USA 0
NCT05400122 Phase I Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Recruiting USA 0
NCT05401097 Phase II Azacitidine + Enasidenib + Venetoclax Azacitidine + Ivosidenib + Venetoclax IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) Recruiting USA 0
NCT05406817 Phase I Revumenib Study of Radiolabeled SNDX-5613 in Adults With Acute Myeloid Leukemia Recruiting USA 0
NCT05424380 Phase I GSK3745417 A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS Terminated NLD | ITA | ESP | DEU | CAN 0
NCT05428969 Phase Ib/II Azacitidine + FP-1305 Azacitidine + FP-1305 + Venetoclax A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB) Recruiting USA | FIN 0
NCT05431257 Phase II Azacitidine + Venetoclax Venetoclax Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling (LD-VenEx) Recruiting DNK 0
NCT05441514 Phase I Cobimetinib + Enasidenib Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT05447663 Phase Ib/II Siremadlin A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant Terminated ITA | ESP | DEU 0
NCT05453903 Phase I JNJ-75276617 + Venetoclax Azacitidine + JNJ-75276617 + Venetoclax Azacitidine + JNJ-75276617 A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies Recruiting USA | ITA | GBR | FRA | ESP | DEU | AUS 0
NCT05455294 Phase I Decitabine + Navitoclax + Venetoclax Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms Active, not recruiting USA 0
NCT05457010 Phase I ACLX-002 Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS Recruiting USA 0
NCT05470140 Phase I WU-NK-101 A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Active, not recruiting USA | AUS 0
NCT05476770 Phase I Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Tagraxofusp-erzs + Vincristine Sulfate Azacitidine + Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Fludarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Recruiting USA | AUS 0
NCT05506332 Phase I Mercaptopurine + Venetoclax Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia Recruiting BEL 0
NCT05506956 Phase I Flotetuzumab Post-transplant Flotetuzumab for AML Completed USA 0
NCT05519527 Phase I STI-6129 A Phase 1, Open-Label, Dose-Escalation Study of Safety And Efficacy of An Anti-CD38 Antibody Drug Conjugate (STI-6129) In Patients With Relapsed Or Refractory T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) Or Acute Myeloid Leukemia (AML) Withdrawn 0
NCT05520567 Phase Ib/II Azacitidine + Gilteritinib + Venetoclax A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia Recruiting USA 0
NCT05546580 Phase I Gilteritinib + ORY-1001 Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (FRIDA) Recruiting USA 0
NCT05554393 Phase II Cytarabine + Daunorubicin Cytarabine + Daunorubicin + Venetoclax Azacitidine + Venetoclax Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) Recruiting USA | CAN 1
NCT05554406 Phase II Cytarabine + Daunorubicin Azacitidine + Venetoclax CPX-351 Cytarabine + Daunorubicin + Venetoclax CPX-351 + Venetoclax Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Recruiting USA 1
NCT05558124 Phase I CPX-351 + Gemtuzumab ozogamicin CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML Recruiting USA 0
NCT05564390 Phase II Cytarabine + Venetoclax Cytarabine + Daunorubicin + Venetoclax CPX-351 + Venetoclax Cytarabine + Daunorubicin Cytarabine Azacitidine + Gilteritinib + Venetoclax Azacitidine + Venetoclax CPX-351 MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Recruiting USA | CAN 1
NCT05580601 Phase Ib/II CIML-NK cells Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) Recruiting USA 0
NCT05583552 Phase II Imetelstat Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress) Recruiting FRA | DEU | AUS 0
NCT05597306 Phase I IMG-7289 + Venetoclax Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia (VenBom) Recruiting USA 0
NCT05599360 Phase II CPX-351 + Gemtuzumab ozogamicin Vyxeos for Induction of Low- or Intermediate-risk. Active, not recruiting ISR 0
NCT05601726 Phase I ABD-3001 First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients (ODYSSEY) Recruiting FRA 0
NCT05627232 Phase I CPX-351 + Palbociclib + Tazemetostat Palbociclib and Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT05636514 Phase I Decitabine and Cedazuridine + Defactinib Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (CELESTIAL-MDS) Recruiting AUS 0
NCT05659732 Phase I PEP07 A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer Recruiting AUS 1
NCT05662904 Phase I Gemtuzumab ozogamicin Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML (GALAXY33) Not yet recruiting DEU 0
NCT05672147 Phase I Anti-CD33 CAR-T cells CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT05673057 Phase Ib/II MP0533 Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting NLD | LTU | FRA | CHE 0
NCT05682170 Phase Ib/II ZN-c3 + ZN-d5 ZN-c3 Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) Terminated USA 0
NCT05697510 Phase I Siltuximab Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM (SILTUXILAM) Recruiting FRA 0
NCT05703542 Phase I Talabostat mesylate BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting USA 0
NCT05712278 Phase I SAR445419 Cytarabine + Fludarabine A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia Terminated USA 0
NCT05720988 Phase I Tagraxofusp-erzs Azacitidine + Tagraxofusp-erzs Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia Withdrawn USA 0
NCT05732103 Phase Ib/II CTX-712 A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes Recruiting USA 0
NCT05735184 Phase I Azacitidine + Venetoclax + Ziftomenib Cytarabine + Daunorubicin + Ziftomenib Venetoclax + Ziftomenib A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML Recruiting USA 0
NCT05744739 Phase I Azacitidine + Tomivosertib + Venetoclax Tomivosertib With Azacitide and Venetoclax for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Suitable for Intensive Chemotherapy Active, not recruiting USA 0
NCT05748197 Phase I Cyclophosphamide + Fludarabine ADCLEC.syn1 A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia Recruiting USA 0
NCT05756322 Phase Ib/II LBS-007 The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias Recruiting USA | AUS 1
NCT05756777 Phase I Gilteritinib + Ivosidenib Enasidenib + Gilteritinib A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) Recruiting USA 0
NCT05766514 Phase II Cladribine + Cytarabine + Decitabine Decitabine + Venetoclax Azacitidine + Venetoclax Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction Not yet recruiting USA 0
NCT05775406 Phase I KT-253 Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors Active, not recruiting USA 0
NCT05780879 Phase II Cytarabine + Filgrastim + Fludarabine + Venetoclax A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia Recruiting USA 0
NCT05787496 Phase I NC525 A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms Active, not recruiting USA 0
NCT05799079 Phase II Decitabine and Cedazuridine + Venetoclax Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant Recruiting USA 0
NCT05817058 Phase I AFM28 First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Recruiting FRA | ESP | DNK 0
NCT05829226 Phase I LYT-200 A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) Recruiting USA 0
NCT05834244 Phase I Azacitidine + Venetoclax A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) Recruiting USA 0
NCT05854966 Phase II CPI-613 + Metformin CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Withdrawn 0
NCT05886049 Phase I Cytarabine + Daunorubicin + Revumenib Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene Recruiting USA 0
NCT05886491 Phase Ib/II Cyclophosphamide + Fludarabine GDX012 A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT05907057 Phase III Azacitidine + Ivosidenib An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. Recruiting NLD | ITA | FRA | AUT 0
NCT05918692 Phase I BMF-500 A Phase 1, Study of BMF-500 in Adults With Acute Leukemia Recruiting USA 0
NCT05933070 Phase I INKmune A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (LAUREL) Terminated GRC | GBR 0
NCT05945849 Phase I Anti-CD33 CAR-T cells CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML Recruiting USA 0
NCT05949125 Phase I Cyclophosphamide + Fludarabine AVC-201 Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 Recruiting NLD | DEU 0
NCT05955261 Phase II Azacitidine + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Gemtuzumab ozogamicin + Gilteritinib + Idarubicin + Venetoclax Cytarabine + Daunorubicin + Etoposide + Fludarabine + Gemtuzumab ozogamicin + Gilteritinib + Idarubicin + mitoxantrone hydrochloride + Venetoclax Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin + Gilteritinib + mitoxantrone hydrochloride + Venetoclax A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia Recruiting USA 0
NCT05961839 Phase I SGR-2921 Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting USA 0
NCT05984199 Phase Ib/II Anti-CD33 CAR-T cells Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant Recruiting USA 0
NCT06001788 Phase I Gilteritinib + Ziftomenib Cytarabine + Ziftomenib Cytarabine + Filgrastim + Fludarabine + Idarubicin + Ziftomenib Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT06007911 Phase I Cladribine + Cytarabine + Navitoclax + Venetoclax Cladribine + Cytarabine + Filgrastim + Mitoxantrone + Navitoclax + Venetoclax Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia Withdrawn USA 0